Rolf Kiessling

Publications
CV
Public outreach and news

Articles

Article: SCIENCE TRANSLATIONAL MEDICINE. 2024;16(747):eadi2952
Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis
Neo SY; Tong L; Chong J; Liu Y; Jing X; Oliveira MMS; Chen Y; Chen Z; Lee K; Burduli N; Chen X; Gao J; Ma R; Lim JP; Huo J; Xu S; Alici E; Wickstrom SL; Haglund F; Hartman J; Wagner AK; Cao Y; Kiessling R; Lam KP; Westerberg LS; Lundqvist A
Article: ONCOIMMUNOLOGY. 2022;11(1):2093426
Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality
Schoutrop E; Renken S; Micallef Nilsson I; Hahn P; Poiret T; Kiessling R; Wickstrom SL; Mattsson J; Magalhaes I
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2022;10(6):e004458
Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress
Renken S; Nakajima T; Magalhaes I; Mattsson J; Lundqvist A; Arner ESJ; Kiessling R; Wickstrom SL
Article: FRONTIERS IN ONCOLOGY. 2022;12:866763
Generation of Tumor-Specific Cytotoxic T Cells From Blood via In Vitro Expansion Using Autologous Dendritic Cells Pulsed With Neoantigen-Coupled Microbeads
Kiessling A; Ramanathan K; Nilsson OB; Notari L; Renken S; Kiessling R; Gronlund H; Wickstrom SL
Journal article: MOLECULAR CANCER THERAPEUTICS. 2021;20(12_Supplement):p109
Abstract P109: Targeting BRD4 in T cells with self-delivering RNAi PH-894 for immunotherapy
Maxwell M; Ujiie D; Cuiffo B; Rivest B; Yan D; Cardia J; Melief J; Kiessling R; Fricker SP
Journal article: ADVANCED SCIENCE. 2021;8(21)
Interleukin‐33 is a Novel Immunosuppressor that Protects Cancer Cells from TIL Killing by a Macrophage‐Mediated Shedding Mechanism (Adv. Sci. 21/2021)
Wu J; Chen Z; Wickström SL; Gao J; He X; Jing X; Wu J; Du Q; Yang M; Chen Y; Zhang D; Yin X; Guo Z; Jensen L; Yang Y; Tao W; Lundqvist A; Kiessling R; Cao Y
Article: ADVANCED SCIENCE. 2021;8(21):e2101029
Interleukin-33 is a Novel Immunosuppressor that Protects Cancer Cells from TIL Killing by a Macrophage-Mediated Shedding Mechanism
Wu J; Chen Z; Wickstrom SL; Gao J; He X; Jing X; Wu J; Du Q; Yang M; Chen Y; Zhang D; Yin X; Guo Z; Jensen L; Yang Y; Tao W; Lundqvist A; Kiessling R; Cao Y
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2021;9(5):e002171
Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+monocytes in the blood
Pour SR; de Coana YP; Martinez Demorentin X; Melief J; Thimma M; Wolodarski M; Gomez-Cabrero D; Hansson J; Kiessling R; Tegner J
Article: ONCOIMMUNOLOGY. 2021;10(1):1935557
Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients
Van Wigcheren GF; De Haas N; Mulder TA; Horrevorts SK; Bloemendal M; Hins-Debree S; Mao Y; Kiessling R; van Herpen CML; Florez-Grau G; Hato SV; De Vries IJM
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2020;117(50):32005-32016
Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells
Eisinger S; Sarhan D; Boura VF; Ibarlucea-Benitez I; Tyystjarvi S; Oliynyk G; Arsenian-Henriksson M; Lane D; Wikstrom SL; Kiessling R; Virgilio T; Gonzalez SF; Kaczynska D; Kanatani S; Daskalaki E; Wheelock CE; Sedimbi S; Chambers BJ; Ravetch JV; Karlsson MCI
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2020;117(37):22910-22919
Visualization of human T lymphocyte-mediated eradication of cancer cells in vivo
He X; Yin X; Wu J; Wickstrom SL; Duo Y; Du Q; Qin S; Yao S; Jing X; Hosaka K; Wu J; Jensen LD; Lundqvist A; Salter AI; Brautigam L; Tao W; Chen Y; Kiessling R; Cao Y
Article: ONCOIMMUNOLOGY. 2020;9(1):1786888
PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates
de Coana YP; Wolodarski M; Avila IVDH; Nakajima T; Rentouli S; Lundqvist A; Masucci G; Hansson J; Kiessling R
Article: CANCERS. 2020;12(9):E2349-2349
Caveolin-1-Mediated Tumor Suppression Is Linked to Reduced HIF1α S-Nitrosylation and Transcriptional Activity in Hypoxia
Sanhueza C; Bennett JC; Valenzuela-Valderrama M; Contreras P; Lobos-Gonzalez L; Campos A; Wehinger S; Lladser A; Kiessling R; Leyton L; Quest AFG
Article: CLINICAL CANCER RESEARCH. 2020;26(16):4289-4301
The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones
Poschke IC; Hassel JC; Rodriguez-Ehrenfried A; Lindner KAM; Heras-Murillo I; Appel LM; Lehmann J; Lovgren T; Wickstrom SL; Lauenstein C; Roth J; Koenig A-K; Haanen JBAG; van den Berg J; Kiessling R; Bergmann F; Flossdorf M; Strobel O; Offringa R
Article: ONCOIMMUNOLOGY. 2020;9(1):1792058
Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination
Lovgren T; Wolodarski M; Wickstrom S; Edback U; Wallin M; Martell E; Markland K; Blomberg P; Nystrom M; Lundqvist A; Jacobsson H; Ullenhag G; Ljungman P; Hansson J; Masucci G; Tell R; Poschke I; Adamson L; Mattsson J; Kiessling R
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2020;69(4):513-522
High expression of ID1 in monocytes is strongly associated with phenotypic and functional MDSC markers in advanced melanoma
Melief J; de Coana YP; Maas R; Fennemann F-L; Wolodarski M; Hansson J; Kiessling R
Article: METHODS IN MOLECULAR BIOLOGY. 2019;1913:207-215
Establishment of Melanoma Tumor Xenograft Using Single Cell Line Suspension and Co-injection of Patient-Derived T Cells in Immune-Deficient NSG Mice.
Gunnarsdóttir FB; Kiessling R; Pico de Coaña Y
Article: METHODS IN MOLECULAR BIOLOGY. 2019;1913:181-194
Evaluating Antibody-Dependent Cell-Mediated Cytotoxicity by Flow Cytometry.
van der Haar Àvila I; Marmol P; Cany J; Kiessling R; Pico de Coaña Y
Article: METHODS IN MOLECULAR BIOLOGY. 2019;1913:167-179
Evaluating Antibody-Dependent Cell-Mediated Cytotoxicity by Chromium Release Assay.
van der Haar Àvila I; Marmol P; Kiessling R; Pico de Coaña Y
Article: METHODS IN MOLECULAR BIOLOGY. 2019;1913:133-140
Assessment of Antitumor T-Cell Responses by Flow Cytometry After Coculture of Tumor Cells with Autologous Tumor-Infiltrating Lymphocytes.
Melief J; Wickström S; Kiessling R; Pico de Coaña Y
Article: FRONTIERS IN IMMUNOLOGY. 2019;10:2766
Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display
Wickstrom SL; Loevgren T; Volkmar M; Reinhold B; Duke-Cohan JS; Hartmann L; Rebmann J; Mueller A; Melief J; Maas R; Ligtenberg M; Hansson J; Offringa R; Seliger B; Poschke I; Reinherz EL; Kiessling R
Article: CANCER IMMUNOLOGY RESEARCH. 2018;6(11):1417-1425
Cripto-1 Plasmid DNA Vaccination Targets Metastasis and Cancer Stem Cells in Murine Mammary Carcinoma
Witt K; Ligtenberg MA; Conti L; Lanzardo S; Ruiu R; Wallmann T; Tufvesson-Stiller H; Chambers BJ; Rolny C; Lladser A; Lundqvist A; Cavallo F; Kiessling R
Article: MOLECULAR THERAPY. 2018;26(6):1482-1493
Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma
Ligtenberg MA; de Coana YP; Shmushkovich T; Yoshimoto Y; Truxova I; Yang Y; Betancur-Boissel M; Eliseev AV; Wolfson AD; Kiessling R
Article: ONCOTARGET. 2017;8(57):97439-97463
Linking CREB function with altered metabolism in murine fibroblast-based model cell lines
Steven A; Leisz S; Wickenhauser C; Schulz K; Mougiakakos D; Kiessling R; Denkert C; Seliger B
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2017;66(10):1333-1344
Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists
Lovgren T; Sarhan D; Truxova I; Choudhary B; Maas R; Melief J; Nystrom M; Edback U; Vermeij R; Scurti G; Nishimura M; Masucci G; Karlsson-Parra A; Lundqvist A; Adamson L; Kiessling R
Article: ONCOTARGET. 2017;8(13):21539-21553
Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma
de Coana YP; Wolodarski M; Poschke I; Yoshimoto Y; Yang Y; Nystrom M; Edback U; Brage SE; Lundqvist A; Masucci GV; Hansson J; Kiessling R
Article: ONCOIMMUNOLOGY. 2017;6(2):e1261242
IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients
Tallerico RA; Cristiani CMA; Staaf EB; Garofalo CA; Sottile RA; Capone MC; de Coana YPD; Madonna GC; Palella EA; Wolodarski MD; Carannante VB; Mallardo DC; Simeone EC; Grimaldi AMC; Johansson SB; Frumento PE; Gulletta EF; Anichini AG; Colucci FH; Ciliberto GI; Kiessling RD; Kaerre KB; Ascierto PAC; Carbone EA
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2017;5:52
Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma
Laurell A; Lonnemark M; Brekkan E; Magnusson A; Tolf A; Wallgren AC; Andersson B; Adamson L; Kiessling R; Karlsson-Parra A
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2016;4:62
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, December 5th 2015
Ascierto PA; Ascierto ML; Formenti S; Gnjatic S; Hammers H; Hirsh V; Kiessling R; Melero I; Nanda R; Pawelec G; Pignata S; Romero P; Speiser DE; Fox BA; Marincola FM
Journal article: CANCER IMMUNOLOGY RESEARCH. 2016;4(11):b026
MDSCs and CD8 effector memory T cells correlate with survival in melanoma patients treated with ipilimumab
De Coana YP; Wolodarski M; Poschke I; Yoshimoto Y; Masucci G; Hansson J; Kiessling R
Article: BLOOD. 2016;128(11):1475-1489
IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells
Mao Y; van Hoef V; Zhang X; Wennerberg E; Lorent J; Witt K; Masvidal L; Liang S; Murray S; Larsson O; Kiessling R; Lundqvist A
Article: ONCOTARGET. 2016;7(32):52061-52084
Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localization
Steven A; Leisz S; Sychra K; Hiebl B; Wickenhauser C; Mougiakakos D; Kiessling R; Denkert C; Seliger B
Article: CLINICAL CANCER RESEARCH. 2016;22(15):3849-3859
Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma
Mao Y; Eissler N; Le Blanc K; Johnsen JI; Kogner P; Kiessling R
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2016;14(1):227
Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer
Miyan M; Schmidt-Mende J; Kiessling R; Poschke I; de Boniface J
Journal article: JOURNAL OF TRANSLATIONAL MEDICINE. 2016;14(1):65
Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.
Nanda VGY; Peng W; Hwu P; Davies MA; Ciliberto G; Fattore L; Malpicci D; Aurisicchio L; Ascierto PA; Croce CM; Mancini R; Spranger S; Gajewski TF; Wang Y; Ferrone S; Vanpouille-Box C; Wennerberg E; Pilones KA; Formenti SC; Demaria S; Tang H; Wang Y; Fu Y-X; Dummer R; Puzanov I; Tarhini A; Chauvin J-M; Pagliano O; Fourcade J; Sun Z; Wang H; Sanders C; Kirkwood JM; Chen T-HT; Maurer M; Korman AJ; Zarour HM; Stroncek DF; Huber V; Rivoltini L; Thurin M; Rau T; Lugli A; Pagès F; Camarero J; Sancho A; Jommi C; de Coaña YP; Wolodarski M; Yoshimoto Y; Gentilcore G; Poschke I; Masucci GV; Hansson J; Kiessling R; Scognamiglio G; Sabbatino F; Marino FZ; Anniciello AM; Cantile M; Cerrone M; Scala S; D’alterio C; Ianaro A; Cirin G; Liguori G; Bott G; Chapman PB; Robert C; Larkin J; Haanen JB; Ribas A; Hogg D; Hamid O; Testori A; Lorigan P; Sosman JA; Flaherty KT; Yue H; Coleman S; Caro I; Hauschild A; McArthur GA; Sznol M; Callahan MK; Kluger H; Postow MA; Gordan R; Segal NH; Rizvi NA; Lesokhin A; Atkins MB; Burke MM; Ralabate A; Rivera A; Kronenberg SA; Agunwamba B; Ruisi M; Horak C; Jiang J; Wolchok J; Ascierto PA; Liszkay G; Maio M; Mandalà M; Demidov L; Stoyakovskiy D; Thomas L; de la Cruz-Merino L; Atkinson V; Dutriaux C; Garbe C; Wongchenko M; Chang I; Koralek DO; Rooney I; Yan Y; Dréno B; Sullivan R; Patel M; Hodi S; Amaria R; Boasberg P; Wallin J; He X; Cha E; Richie N; Ballinger M; Smith DC; Bauer TM; Wasser JS; Luke JJ; Balmanoukian AS; Kaufman DR; Zhao Y; Maleski J; Leopold L; Gangadhar TC; Long GV; Michielin O; VanderWalde A; Andtbacka RHI; Cebon J; Fernandez E; Malvehy J; Olszanski AJ; Gause C; Chen L; Chou J; Stephen Hodi F; Brady B; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Lebbé C; Ny L; Chacon M; Queirolo P; Loquai C; Cheema P; Berrocal A; Eizmendi KM; Bar-Sela G; Horak C; Hardy H; Weber JS; Grob J-J; Marquez-Rodas I; Schmidt H; Briscoe K; Baurain J-F; Wolchok JD; Pinto R; De Summa S; Garrisi VM; Strippoli S; Azzariti A; Guida G; Guida M; Tommasi S; Jacquelot N; Enot D; Flament C; Pitt JM; Vimond N; Blattner C; Yamazaki T; Roberti M-P; Vetizou M; Daillere R; Poirier-Colame V; la Semeraro M; Caignard A; Slingluff CL; Sallusto F; Rusakiewicz S; Weide B; Marabelle A; Kohrt H; Dalle S; Cavalcanti A; Kroemer G; Di Giacomo AM; Maio M; Wong P; Yuan J; Umansky V; Eggermont A; Zitvogel L; Anna P; Marco T; Stefania S; Francesco M; Mariaelena C; Gabriele M; Antonio AP; Franco S; Roberti MP; Enot DP; Semeraro M; Jégou S; Flores C; Chen T-HT; Kwon BS; Anderson AC; Borg C; Aubin F; Ayyoub M; De Presbiteris AL; Cordaro FG; Camerlingo R; Fratangelo F; Mozzillo N; Pirozzi G; Patriarca EJ; Caputo E; Motti ML; Falcon R; Miceli R; Capone M; Madonna G; Mallardo D; Carrier MV; Panza E; De Cicco P; Armogida C; Ercolano G; Botti G; Cirino G; Sandru A; Blank M; Balatoni T; Olasz J; Farkas E; Szollar A; Savolt A; Godeny M; Csuka O; Horvath S; Eles K; Shoenfeld Y; Kasler M; Costantini S; Capone F; Moradi F; Berglund P; Leandersson K; Linnskog R; Andersson T; Prasad CP; Nigro CL; Lattanzio L; Wang H; Proby C; Syed N; Occelli M; Cauchi C; Merlano M; Harwood C; Thompson A; Crook T; Bifulco K; Ingangi V; Minopoli M; Ragone C; Pessi A; Mannavola F; D’Oronzo S; Felici C; Tucci M; Doronzo A; Silvestris F; Ferretta A; Guida S; Maida I; Cocco T; Passarelli A; Quaresmini D; Franzese O; Palermo B; Di Donna C; Sperduti I; Foddai M; Stabile H; Gismondi A; Santoni A; Nisticò P; Sponghini AP; Platini F; Marra E; Rondonotti D; Alabiso O; Fierro MT; Savoia P; Stratica F; Quaglino P; Di Monta G; Corrado C; Di Marzo M; Ugo M; Di Cecilia ML; Nicola M; Fusciello C; Marra A; Guarrasi R; Baldi C; Russo R; Di Giulio G; Faiola V; Zeppa P; Pepe S; Gambale E; Carella C; Di Paolo A; De Tursi M; Marra L; De Murtas F; Sorrentino V; Voinea S; Panaitescu E; Bolovan M; Stanciu A; Cinca S; Botti C; Aquino G; Anniciello A; Fortes C; Mastroeni S; Caggiati A; Passarelli F; Zappalà A; Capuano M; Bono R; Nudo M; Marino C; Michelozzi P; De Biasio V; Battarra VC; Formenti S; Ascierto ML; McMiller TL; Berger AE; Danilova L; Anders RA; Netto GJ; Xu H; Pritchard TS; Fan J; Cheadle C; Cope L; Drake CG; Pardoll DM; Taube JM; Topalian SL; Gnjatic S; Nataraj S; Imai N; Rahman A; Jungbluth AA; Pan L; Venhaus R; Park A; Lehmann FF; Lendvai N; Cohen AD; Cho HJ; Daniel S; Hirsh V
Article: ONCOIMMUNOLOGY. 2016;5(5):e1128613
Cripto-1 vaccination elicits protective immunity against metastatic melanoma
Ligtenberg MA; Witt K; Galvez-Cancino F; Sette A; Lundqvist A; Lladser A; Kiessling R
Article: JOURNAL OF IMMUNOLOGY. 2016;196(2):759-766
Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity
Ligtenberg MA; Mougiakakos D; Mukhopadhyay M; Witt K; Lladser A; Chmielewski M; Riet T; Abken H; Kiessling R
Article: ONCOIMMUNOLOGY. 2016;5(1):e1052213
Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis
Andersson E; Poschke I; Villabona L; Carlson JW; Lundqvist A; Kiessling R; Seliger B; Masucci GV
Article: ONCOIMMUNOLOGY. 2016;5(12):e1232222
Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade
Eissler N; Mao Y; Brodin D; Reutersward P; Svahn HA; Johnsen JI; Kiessling R; Kogner P
Journal article: JOURNAL OF TRANSLATIONAL MEDICINE. 2015;13(Suppl 1):o7
Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation
Pico de Coaña Y; Wolodarski M; Gentilcore G; Yoshimoto Y; Poschke I; Hansson J; Masucci GV; Kiessling R
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2015;13:374
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Mc Arthur G; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
Article: HUMAN GENE THERAPY. CLINICAL DEVELOPMENT. 2015;26(2):79-81
Adoptive Engineered T-Cell Trials to Achieve Cancer Killing (ATTACK)
Hawkins R; Gilham D; Sleijfer S; Lamers C; Debets R; Kiessling R; Thistlethwaite F; Lorigan P; Taylor N; Guest R; Chao D; Assenmacher M; Kaiser A; Schumacher T; Haanen J; Nuijen B; van den Berg J; Jakobsen B; Hildich T; Hochhauser D; Morris E; Kiessling R; Tell R; Mondino A; Bonini C
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2015;45(6):1783-1793
Dendritic cell regulation of NK-cell responses involves lymphotoxin-, IL-12, and TGF-
Sarhan D; Palma M; Mao Y; Adamson L; Kiessling R; Mellstedt H; Osterborg A; Lundqvist A
Article: ONCOIMMUNOLOGY. 2015;4(4):e998538
Consensus nomenclature for CD8⁺ T cell phenotypes in cancer
Apetoh L; Smyth MJ; Drake CG; Abastado J-P; Apte RN; Ayyoub M; Blay J-Y; Bonneville M; Butterfield LH; Caignard A; Castelli C; Cavallo F; Celis E; Chen L; Colombo MP; Comin-Anduix B; Coukos G; Dhodapkar MV; Dranoff G; Frazer IH; Fridman W-H; Gabrilovich DI; Gilboa E; Gnjatic S; Jaeger D; Kalinski P; Kaufman HL; Kiessling R; Kirkwood J; Knuth A; Liblau R; Lotze MT; Lugli E; Marincola F; Melero I; Melief CJ; Mempel TR; Mittendorf EA; Odun K; Overwijk WW; Palucka AK; Parmiani G; Ribas A; Romero P; Schreiber RD; Schuler G; Srivastava PK; Tartour E; Valmori D; van der Burg SH; van der Bruggen P; van den Eynde BJ; Wang E; Zou W; Whiteside TL; Speiser DE; Pardoll DM; Restifo NP; Anderson AC
Journal article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2015;3(Suppl 2):p232
Interleukin-15 potentiates human natural killer cells to resist tumor-induced suppression through mTOR-regulated metabolic control
Lundqvist A; Mao Y; Zhang X; Wennerberg E; Van Hoef V; Larsson O; Linder S; Kiessling R
Article: PLOS ONE. 2015;10(6):e0129786
Methylcholanthrene-Induced Sarcomas Develop Independently from NOX2-Derived ROS
Ligtenberg MA; Cinar O; Holmdahl R; Mougiakakos D; Kiessling R
Article: PLOS ONE. 2015;10(10):e0139809
Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells
Okita R; Wolf D; Yasuda K; Maeda A; Yukawa T; Saisho S; Shimizu K; Yamaguchi Y; Oka M; Nakayama E; Lundqvist A; Kiessling R; Seliger B; Nakata M
Journal article: ONCOTARGET. 2014;5(24):12472-12508
Classification of current anticancer immunotherapies
Galluzzi L; Vacchelli E; Pedro J-MB-S; Buqué A; Senovilla L; Baracco EE; Bloy N; Castoldi F; Abastado J-P; Agostinis P; Apte RN; Aranda F; Ayyoub M; Beckhove P; Blay J-Y; Bracci L; Caignard A; Castelli C; Cavallo F; Celis E; Cerundolo V; Clayton A; Colombo MP; Coussens L; Dhodapkar MV; Eggermont AM; Fearon DT; Fridman WH; Fučíková J; Gabrilovich DI; Galon J; Garg A; Ghiringhelli F; Giaccone G; Gilboa E; Gnjatic S; Hoos A; Hosmalin A; Jäger D; Kalinski P; Kärre K; Kepp O; Kiessling R; Kirkwood JM; Klein E; Knuth A; Lewis CE; Liblau R; Lotze MT; Lugli E; Mach J-P; Mattei F; Mavilio D; Melero I; Melief CJ; Mittendorf EA; Moretta L; Odunsi A; Okada H; Palucka AK; Peter ME; Pienta KJ; Porgador A; Prendergast GC; Rabinovich GA; Restifo NP; Rizvi N; Sautès-Fridman C; Schreiber H; Seliger B; Shiku H; Silva-Santos B; Smyth MJ; Speiser DE; Spisek R; Srivastava PK; Talmadge JE; Tartour E; Van Der Burg SH; Van Den Eynde BJ; Vile R; Wagner H; Weber JS; Whiteside TL; Wolchok JD; Zitvogel L; Zou W; Kroemer G
Journal article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2014;2(Suppl 3):p231
Ipilimumab treatment enhances CD4+ T cell activation while decreasing Treg and MDSC frequency in advanced melanoma patients
Pico de Coaña Y; Poschke I; Yoshimoto Y; Karlberg S; Nyström M; Wolodarski M; Hansson J; Masucci G; Kiessling R
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2014;63(10):1061-1071
A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma
Poschke I; Lovgren T; Adamson L; Nystrom M; Andersson E; Hansson J; Tell R; Masucci GV; Kiessling R
Article: MATRIX BIOLOGY. 2014;38:69-83
Laminins 411 and 421 differentially promote tumor cell migration via α6β1 integrin and MCAM (CD146)
Ishikawa T; Wondimu Z; Oikawa Y; Gentilcore G; Kiessling R; Brage SE; Hansson J; Patarroyo M
Article: CLINICAL CANCER RESEARCH. 2014;20(15):4096-4106
Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity
Mao Y; Sarhan D; Steven A; Seliger B; Kiessling R; Lundqvist A
Journal article: CRITICAL REVIEWS IN ONCOGENESIS. 2014;19(1-2):15-19
Serendipity. Coincidence. Luck.
Kiessling R
Journal article: JOURNAL OF TRANSLATIONAL MEDICINE. 2014;12(Suppl 1):o9
Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid derived suppressor cells as well as their arginase 1 production
Gentilcore G; Pico de Yago C; Poschke I; Mao Y; Nyström M; Hansson J; Masucci GV; Kiessling R
Article: JOURNAL OF IMMUNOLOGY. 2013;191(12):6261-6272
The MAPK Pathway Is a Predominant Regulator of HLA-A Expression in Esophageal and Gastric Cancer
Mimura K; Shiraishi K; Mueller A; Izawa S; Kua L-F; So J; Yong W-P; Fujii H; Seliger B; Kiessling R; Kono K
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2013;11:290
Tumor-dependent increase of serum amino acid levels in breast cancer patients has diagnostic potential and correlates with molecular tumor subtypes
Poschke I; Mao Y; Kiessling R; de Boniface J
Article: HUMAN VACCINES & IMMUNOTHERAPEUTICS. 2013;9(10):2189-2195
NF-κB activation during intradermal DNA vaccination is essential for eliciting tumor protective antigen-specific CTL responses
Ligtenberg MA; Rojas-Colonelli N; Kiessling R; Lladser A
Article: CANCER IMMUNOLOGY RESEARCH. 2013;1(3):158-162
Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase1 Production
de Coana YP; Poschke I; Gentilcore G; Mao Y; Nystrom M; Hansson J; Masucci GV; Kiessling R
Article: STEM CELLS. 2013;31(8):1715-1725
Alterations in the Cellular Immune Compartment of Patients Treated with Third-Party Mesenchymal Stromal Cells Following Allogeneic Hematopoietic Stem Cell Transplantation
Jitschin R; Mougiakakos D; Von Bahr L; Voelkl S; Moll G; Ringden O; Kiessling R; Linder S; Le Blanc K
Article: CANCER RESEARCH. 2013;73(13):3877-3887
Melanoma-Educated CD14⁺ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2-Dependent Mechanisms
Mao Y; Poschke I; Wennerberg E; de Coana YP; Brage SE; Schultz I; Hansson J; Masucci G; Lundqvist A; Kiessling R
Article: ONCOIMMUNOLOGY. 2012;1(8):1305-1312
Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients
de Boniface J; Mao Y; Schmidt-Mende J; Kiessling R; Poschke I
Article: ONCOIMMUNOLOGY. 2012;1(7):1104-1110
Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression
Inoue M; Mimura K; Izawa S; Shiraishi K; Inoue A; Shiba S; Watanabe M; Maruyama T; Kawaguchi Y; Inoue S; Kawasaki T; Choudhury A; Katoh R; Fujii H; Kiessling R; Kono K
Article: INTERNATIONAL JOURNAL OF CANCER. 2012;131(7):1611-1620
Tumor-induced changes in the phenotype of blood-derived and tumor-associated T cells of early stage breast cancer patients
Poschke I; De Boniface J; Mao Y; Kiessling R
Journal article: ANNALS OF ONCOLOGY. 2012;23:ix541
1690P Her Signaling Effects on the NK Cell-Mediated Cytotoxicity via Regulation of MHC Class I-Related Chain A/B in Cancer Cells
Okita R; Mougiakakos D; Yasuda K; Maeda A; Yukawa T; Saisho S; Hirami Y; Shimizu K; Nakata M; Kiessling R
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2012;61(8):1243-1253
Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer
Andersson E; Villabona L; Bergfeldt K; Carlson JW; Ferrone S; Kiessling R; Seliger B; Masucci GV
Article: JOURNAL OF MOLECULAR MEDICINE. 2012;90(8):935-944
High expression of GCLC is associated with malignant melanoma of low oxidative phenotype and predicts a better prognosis
Mougiakakos D; Okita R; Ando T; Duerr C; Gadiot J; Ichikawa J; Zeiser R; Blank C; Johansson CC; Kiessling R
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2012;287(29):24320-24329
HER-2/neu-mediated Down-regulation of Biglycan Associated with Altered Growth Properties
Recktenwald CV; Leisz S; Steven A; Mimura K; Mueller A; Wulfaenger J; Kiessling R; Seliger B
Article: INTERNATIONAL JOURNAL OF CANCER. 2012;131(1):129-139
Tumor-dependent down-regulation of the ζ-chain in T-cells is detectable in early breast cancer and correlates with immune cell function
De Boniface J; Poschke I; Mao Y; Kiessling R
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2012;61(6):827-838
Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines
Poschke I; Mao Y; Adamson L; Salazar-Onfray F; Masucci G; Kiessling R
Article: INTERNATIONAL JOURNAL OF CANCER. 2012;130(5):1120-1127
Nuclear HER3 is associated with favorable overall survival in uveal melanoma
Trocme E; Mougiakakos D; Johansson CC; All-Eriksson C; Economou MA; Larsson O; Seregard S; Kiessling R; Lin Y
Article: JOURNAL OF IMMUNOLOGY. 2012;188(5):2136-2145
HER2/HER3 Signaling Regulates NK Cell-Mediated Cytotoxicity via MHC Class I Chain-Related Molecule A and B Expression in Human Breast Cancer Cell Lines
Okita R; Mougiakakos D; Ando T; Mao Y; Sarhan D; Wennerberg E; Seliger B; Lundqvist A; Mimura K; Kiessling R
Article: PLOS ONE. 2012;7(7):e41345
Comparative Expression Profiling of Distinct T Cell Subsets Undergoing Oxidative Stress
Lichtenfels R; Mougiakakos D; Johansson CC; Dressler SP; Recktenwald CV; Kiessling R; Seliger B
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2011;9:214
Defining the critical hurdles in cancer immunotherapy
Fox BA; Schendel DJ; Butterfield LH; Aamdal S; Allison JP; Ascierto PA; Atkins MB; Bartunkova J; Bergmann L; Berinstein N; Bonorino CC; Borden E; Bramson JL; Britten CM; Cao X; Carson WE; Chang AE; Characiejus D; Choudhury AR; Coukos G; de Gruijl T; Dillman RO; Dolstra H; Dranoff G; Durrant LG; Finke JH; Galon J; Gollob JA; Gouttefangeas C; Grizzi F; Guida M; Hakansson L; Hege K; Herberman RB; Hodi FS; Hoos A; Huber C; Hwu P; Imai K; Jaffee EM; Janetzki S; June CH; Kalinsk P; Kaufman HL; Kawakami K; Kawakami Y; Keilholtz U; Khleif SN; Kiessling R; Kotlan B; Kroemer G; Lapointe R; Levitsky HI; Lotze MT; Maccalli C; Maio M; Marschner J-P; Mastrangelo MJ; Masucci G; Melero I; Melief C; Murphy WJ; Nelson B; Nicolini A; Nishimura MI; Odunsi K; Ohashi PS; O'Donnell-Tormey J; Old LJ; Ottensmeier C; Papamichail M; Parmiani G; Pawelec G; Proietti E; Qin S; Rees R; Ribas A; Ridolfi R; Ritter G; Rivoltini L; Romero PJ; Salem ML; Scheper RJ; Seliger B; Sharma P; Shiku H; Singh-Jasuja H; Song W; Straten PT; Tahara H; Tian Z; van Der Burg SH; von Hoegen P; Wang E; Welters MJP; Winter H; Withington T; Wolchok JD; Xiao W; Zitvogel L; Zwierzina H; Marincola FM; Gajewski TF; Wigginton JM; Disis ML
Article: INTERNATIONAL JOURNAL OF CANCER. 2011;129(10):2408-2416
Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines
Mimura K; Kono K; Maruyama T; Watanabe M; Izawa S; Shiba S; Mizukami Y; Kawaguchi Y; Inoue M; Kono T; Choudhury A; Kiessling R; Fujii H
Article: IMMUNOBIOLOGY. 2011;216(10):1117-1126
A synthetic peptide homologous to IL-10 functional domain induces monocyte differentiation to TGF-β plus tolerogenic dendritic cells
Lopez MN; Pesce B; Kurte M; Perez C; Segal G; Roa J; Carlos Aguillon J; Mendoza-Naranjo A; Gesser B; Larsen C; Villablanca A; Choudhury A; Kiessling R; Salazar-Onfray F
Article: BLOOD. 2011;117(18):4826-4835
The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells
Mougiakakos D; Jitschin R; Johansson CC; Okita R; Kiessling R; Le Blanc K
Article: JOURNAL OF IMMUNOTHERAPY. 2011;34(4):336-342
Multipotent Mesenchymal Stromal Cells Express FoxP3: A Marker for the Immunosuppressive Capacity?
Sundin M; D'Arcy P; Johansson CC; Barrett AJ; Loennies H; Sundberg B; Nava S; Kiessling R; Mougiakakos D; Le Blanc K
Article: MOLECULAR THERAPY. 2011;19(3):594-601
DAI (DLM-1/ZBP1) as a Genetic Adjuvant for DNA Vaccines That Promotes Effective Antitumor CTL Immunity
Lladser A; Mougiakakos D; Tufvesson H; Ligtenberg MA; Quest AFG; Kiessling R; Ljungberg K
Article: BLOOD. 2011;117(3):857-861
Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress
Mougiakakos D; Johansson CC; Jitschin R; Bottcher M; Kiessling R
Article: INTERNATIONAL JOURNAL OF CANCER. 2011;128(2):390-401
T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2
Mimura K; Ando T; Poschke I; Mougiakakos D; Johansson CC; Ichikawa J; Okita R; Nishimura MI; Handke D; Krug N; Choudhury A; Seliger B; Kiessling R
Article: CANCER RESEARCH. 2010;70(19):7431-7441
Antibody-Dependent Natural Killer Cell-Mediated Cytotoxicity Engendered by a Kinase-Inactive Human HER2 Adenovirus-Based Vaccination Mediates Resistance to Breast Tumors
Triulzi C; Vertuani S; Curcio C; Antognoli A; Seibt J; Akusjarvi G; Wei W-Z; Cavallo F; Kiessling R
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2010;8:53
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial
Norell H; Poschke I; Charo J; Wei WZ; Erskine C; Piechocki MP; Knutson KL; Bergh J; Lidbrink E; Kiessling R
Article: INTERNATIONAL JOURNAL OF CANCER. 2010;126(11):2682-2689
Expression and prognostic significance of iNOS in uveal melanoma
Johansson CC; Mougiakakos D; Trocme E; All-Ericsson C; Economou MA; Larsson O; Seregard S; Kiessling R
Article: CANCER RESEARCH. 2010;70(11):4335-4345
Immature Immunosuppressive CD14⁺HLA-DR^-/low Cells in Melanoma Patients Are Stat3^hi and Overexpress CD80, CD83, and DC-Sign
Poschke I; Mougiakakos D; Hansson J; Masucci GV; Kiessling R
Journal article: JOURNAL OF NUCLEIC ACIDS INVESTIGATION. 2010;1(1):9
Survival of the fittest or best adapted: HLA-dependent tumor development
Masucci GV; Andersson E; Villabona L; Helgadottir H; Bergfeldt K; Cavallo F; Forni G; Ferrone S; Choudhury A; Seliger B; Kiessling R
Article: CANCER. 2010;116(9):2224-2233
Intratumoral Forkhead Box P3-Positive Regulatory T Cells Predict Poor Survival in Cyclooxygenase-2 Positive Uveal Melanoma
Mougiakakos D; Johansson CC; Trocme E; All-Ericsson C; Economou MA; Larsson O; Seregard S; Kiessling R
Journal article: JOURNAL OF NUCLEIC ACIDS INVESTIGATION. 2010;1(1):9
Survival of the fittest or best adapted: HLA-dependent tumor development
Masucci GV; Andersson E; Villabona L; Helgadottir H; Bergfeldt K; Cavallo F; Forni G; Ferrone S; Choudhury A; Seliger B; Kiessling R
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2010;59(1):81-92
Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma
Lladser A; Ljungberg K; Tufvesson H; Tazzari M; Roos A-K; Quest AFG; Kiessling R
Article: JOURNAL OF IMMUNOLOGY. 2009;183(8):4921-4930
Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells
Carlsten M; Norell H; Bryceson YT; Poschke I; Schedvins K; Liunggren H-G; Kiessling R; Malmberg K-J
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2009;58(10):1599-1608
The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma
Helgadottir H; Andersson E; Villabona L; Kanter L; van der Zanden H; Haasnoot GW; Seliger B; Bergfeldt K; Hansson J; Ragnarsson-Olding B; Kiessling R; Masucci GV
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2009;58(7):1085-1094
Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma
Johansson CC; Egyhazi S; Masucci G; Harlin H; Mougiakakos D; Poschke I; Nilsson B; Garberg L; Tuominen R; Linden D; Stolt MF; Hansson J; Kiessling R
Article: EUROPEAN JOURNAL OF CANCER. 2009;45(8):1424-1431
Improving the efficacy of cancer immunotherapy
Copier J; Dalgleish AG; Britten CM; Finke LH; Gaudernack G; Gnjatic S; Kallen K; Kiessling R; Schuessler-Lenz M; Singh H; Talmadge J; Zwierzina H; Hakansson L
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2009;58(5):653-664
HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice
Vertuani S; Triulzi C; Roos AK; Charo J; Norell H; Lemonnier F; Pisa P; Seliger B; Kiessling R
Article: BLOOD. 2009;113(15):3542-3545
Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death
Mougiakakos D; Johansson CC; Kiessling R
Article: JOURNAL OF IMMUNOLOGY. 2008;181(12):8382-8390
Transduction with the Antioxidant Enzyme Catalase Protects Human T Cells against Oxidative Stress
Ando T; Mimura K; Johansson CC; Hanson MG; Mougiakakos D; Larsson C; da Palma TM; Sakurai D; Norell H; Li M; Nishimura MI; Kiessling R
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2008;105(45):17481-17486
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
Kruschinski A; Moosmann A; Poschke I; Norell H; Chmielewski M; Seliger B; Kiessling R; Blankenstein T; Abken H; Charo J
Article: LAKARTIDNINGEN. 2008;105(36):2402-2404
[Therapeutic vaccines against cancer and infectious diseases. Great possibilities in the research--small clinical progress so far].
Kiessling R; Ljungberg K; Von Gabain A
Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2008;99(1):57-64
ANALYSIS OF GAMMA-DELTA-V REGION USAGE IN NORMAL AND DISEASED HUMAN INTESTINAL BIOPSIES AND PERIPHERAL-BLOOD BY POLYMERASE CHAIN-REACTION (PCR) AND FLOW-CYTOMETRY
BUCHT A; SODERSTROM K; ESIN S; GRUNEWALD J; HAGELBERG S; MAGNUSSON I; WIGZELL H; GRONBERG A; KIESSLING R
Journal article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2008;80(3):314-323
SPECIFIC LYSIS OF MYCOBACTERIAL ANTIGEN-BEARING MACROPHAGES BY CLASS-II MHC-RESTRICTED POLYCLONAL T-CELL LINES IN HEALTHY DONORS OR PATIENTS WITH TUBERCULOSIS
KUMARARATNE DS; PITHIE AS; DRYSDALE P; GASTON JSH; KIESSLING R; ILES PB; ELLIS CJ; INNES J; WISE R
Article: JOURNAL OF IMMUNOLOGY. 2008;180(6):3766-3774
Modulation of the tumor cell phenotype by IFN-γ results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes
Hallermalm K; Seki K; De Geer A; Motyka B; Bleackley RC; Jager MJ; Froelich CJ; Kiessling R; Levitsky V; Levitskaya J
Article: JOURNAL OF IMMUNOLOGY. 2007;179(7):4513-4519
The CD16-CD56^bright NK cell subset is resistant to reactive oxygen species produced by activated Granulocytes and has higher antioxidative capacity than the CD16+CD56^dim subset
Harlin H; Hanson M; Johansson CC; Sakurai D; Poschke I; Norell H; Malmberg K-J; Kiessling R
Article: HLA. 2007;70(3):205-213
Analysis of HLA class I-II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer
Gamzatova Z; Villabona L; van der Zanden H; Haasnoot GW; Andersson E; Kiessling R; Seliger B; Kanter L; Dalianis T; Bergfeldt K; Masucci GV
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2007;37(8):2196-2204
IFN-γ regulates Fas ligand expression in human CD4⁺ T lymphocytes and controls their anti-mycobacterial cytotoxic functions
Boselli D; Losana G; Bernabei P; Bosisio D; Drysdale P; Kiessling R; Gaston JSH; Lammas D; Casanova J-L; Kumararatne DS; Novelli F
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2007;56(7):973-984
A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients
Hanson MGV; Ozenci V; Carlsten MCV; Glimelius BL; Frodin J-EA; Masucci G; Malmberg K-J; Kiessling RVR
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2007;25(18_suppl):21059
Lack of p21/Waf-1 expression and lymphocyte infiltration in primary ovarian cancer correlate with the somatic HLA-A2 expression
Andersson E; Villabona L; Kanter L; Gamzatova Z; Kiessling R; Dalianis T; Bergfeldt K; Masucci GV
Article: JOURNAL OF IMMUNOLOGY. 2007;178(11):6949-6957
Functional gap junctions facilitate melanoma antigen transfer and cross-presentation between human dendritic cells
Mendoza-Naranjo A; Saez PJ; Johansson CC; Ramirez M; Mandakovic D; Pereda C; Lopez MN; Kiessling R; Saez JC; Salazar-Onfray F
Article: INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE. 2007;48(3):1219-1227
Melanocortin 1 receptor is expressed by uveal malignant melanoma and can be considered a new target for diagnosis and immunotherapy
Lopez MN; Pereda C; Ramirez M; Mendoza-Naranjo A; Serrano A; Ferreira A; Poblete R; Katergis AM; Kiessling R; Salazar-Onfray F
Article: CANCER RESEARCH. 2007;67(3):1317-1325
DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells
Carlsten M; Bjorkstrom NK; Norell H; Bryceson Y; van Hall T; Baumann BC; Hanson M; Schedvins K; Kiessling R; Ljunggren H-G; Malmberg KJ
Article: JOURNAL OF IMMUNOLOGY. 2006;177(11):7540-7550
Cytotoxic T lymphocytes induce caspase-dependent and -independent cell death in neuroblastomas in a MHC-nonrestricted fashion
De Geer A; Kiessling R; Levitsky V; Levitskaya J
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2006;56(2):193-204
Retinoic acid elicits cytostatic, cytotoxic and immunomodulatory effects on uveal melanoma cells
Vertuani S; Dubrovska E; Levitsky V; Jager MJ; Kiessling R; Levitskaya J
Article: CANCER RESEARCH. 2006;66(12):6387-6394
Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity
Norell H; Carlsten M; Ohlum T; Malmberg K-J; Masucci G; Schedvins K; Altermann W; Handke D; Atkins D; Seliger B; Kiessling R
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2006;103(24):9208-9213
A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth
Holmgren L; Ambrosino E; Birot O; Tullus C; Veitonmaki N; Levchenko T; Carlson L-M; Musiari P; Iezzi M; Curcio C; Forni G; Cavallo F; Kiessling R
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2006;55(6):653-662
Interferon-γ renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells
Kaplan BLF; Norell H; Callender GG; Ohlum T; Kiessling R; Nishimura MI
Article: JOURNAL OF IMMUNOTHERAPY. 2005;28(4):389-395
Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer
Miller AM; Özenci V; Kiessling R; Pisa P
Article: CANCER RESEARCH. 2005;65(13):5953-5957
A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors
Tegerstedt K; Lindencrona JA; Curcio C; Andreasson K; Tullus C; Forni G; Dalianis T; Kiessling R; Ramqvist T
Article: JOURNAL OF IMMUNOLOGY. 2005;174(10):6080-6087
Preferential cell death of CD8⁺ effector memory (CCR7^-CD45RA^-) T cells by hydrogen peroxide-induced oxidative stress
Takahashi A; Hanson MGV; Norell HR; Havelka AM; Kono K; Malmberg KJ; Kiessling RVR
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2004;53(12):1085-1092
Comparison of PSA-specific CD8⁺ CTL responses and antitumor immunity generated by plasmid DNA vaccines encoding PSA-HSP chimeric proteins
Pavlenko M; Roos AK; Leder C; Hansson LO; Kiessling R; Levitskaya E; Pisa P
Article: JOURNAL OF VIROLOGY. 2004;78(20):11321-11326
Protective efficacy of a DNA influenza virus vaccine is markedly increased by the coadministration of a Schiff base-forming drug
Charo J; Lindencrona JA; Carlson LM; Hinkula J; Kiessling R
Article: CANCER RESEARCH. 2004;64(18):6775-6782
Autocrine secretion of fas ligand shields tumor cells from fas-mediated killing by cytotoxic lymphocytes
Hallermalm K; De Geer A; Kiessling R; Levitsky V; Levitskaya J
Article: BRITISH JOURNAL OF CANCER. 2004;91(4):688-694
A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer
Pavlenko M; Roos AK; Lundqvist A; Palmborg A; Miller AM; Ozenci V; Bergman B; Egevad L; Hellström M; Kiessling R; Masucci G; Wersäll P; Nilsson S; Pisa P
Article: JOURNAL OF IMMUNOLOGY. 2004;173(3):1731-1737
A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and transporter associated with antigen processing 1/2 in human melanoma cells
Kurte M; López M; Aguirre A; Escobar A; Aguillón JC; Charo J; Larsen CG; Kiessling R; Salazar-Onfray F
Article: INTERNATIONAL JOURNAL OF CANCER. 2004;109(2):259-264
CD4+T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells
Lindencrona JA; Preiss S; Kammertoens T; Schüler T; Piechocki M; Wei WZ; Seliger B; Blankenstein T; Kiessling R
Article: JOURNAL OF IMMUNOLOGY. 2004;172(6):3501-3508
Improved immunogenicity of an immunodominant epitope of the Her-2/neu protooncogene by alterations of MHC contact residues
Vertuani S; Sette A; Sidney J; Southwood S; Fikes J; Keogh E; Lindencrona JA; Ishioka G; Levitskaya J; Kiessling R
Article: INTERNATIONAL JOURNAL OF CANCER. 2004;108(1):71-77
Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines
Choudhury A; Charo J; Parapuram SK; Hunt RC; Hunt DM; Seliger B; Kiessling R
Article: CYTOTHERAPY. 2004;6(4):363-371
Development of a technology platform for large-scale clinical grade production of DC
Adamson L; Palmborg A; Svensson A; Lundqvist A; Hansson M; Kiessling R; Masucci G; Mellstedt H; Pisa P
Article: CANCER RESEARCH. 2003;63(22):8006-8013
Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes
Vertuani S; De Geer A; Levitsky V; Kogner P; Kiessling R; Levitskaya J
Article: INTERNATIONAL IMMUNOLOGY. 2003;15(6):751-763
Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells
Ramakrishna V; Ross MM; Petersson M; Gatlin CC; Lyons CE; Miller CL; Myers HE; McDaniel M; Karns LR; Kiessling R; Parmiani G; Flyer DC
Article: INFECTION AND IMMUNITY. 2002;70(12):6652-6657
Marked enhancement of the antigen-specific immune response by combining plasmid DNA-Based immunization with a Schiff base-forming drug
Charo J; Sundbäck M; Wasserman K; Ciupitu AMT; Mirzai B; van der Zee R; Kiessling R
Article: JOURNAL OF CLINICAL INVESTIGATION. 2002;110(10):1515-1523
IFN-γ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism
Malmberg KJ; Levitsky V; Norell H; de Matos CT; Carlsten M; Schedvins K; Rabbani H; Moretta A; Söderström K; Levitskaya J; Kiessling R
Article: CLINICAL CANCER RESEARCH. 2002;8(11):3394-3400
Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer
Kono K; Takahashi A; Sugai H; Fujii H; Choudhury AR; Kiessling R; Matsumoto Y
Article: JOURNAL OF HYPERTENSION. 2002;20(9):1815-1820
Circulating heat shock protein and heat shock protein antibody levels in established hypertension
Pockley AG; de Faire U; Kiessling R; Lemne C; Thulin T; Frostegård J
Article: BRITISH JOURNAL OF CANCER. 2002;87(4):414-422
Tissue distribution and differential expression of melanocortin I receptor, a malignant melanoma marker
Salazar-Onfray F; López M; Lundqvist A; Aguirre A; Escobar A; Serrano A; Korenblit C; Petersson M; Chhajlani V; Larsson O; Kiessling R
Article: CLINICAL CANCER RESEARCH. 2002;8(6):1772-1778
A short-term dietary supplementation of high doses of vitamin E increases T helper 1 cytokine production in patients with advanced colorectal cancer
Malmberg KJ; Lenkei R; Petersson M; Ohlum T; Ichihara F; Glimelius B; Frödin JE; Masucci G; Kiessling R
Article: HUMAN IMMUNOLOGY. 2002;63(6):444-451
HLA expression in uveal melanoma: There is no rule without some exception
Jager MJ; Hurks HMH; Levitskaya J; Kiessling R
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2002;51(3):163-170
Immunization with heat shock protein 70 from methylcholanthrene-induced sarcomas induces tumor protection correlating with in vitro T cell responses
Ciupitu AMT; Petersson M; Kono K; Charo J; Kiessling R
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2002;51(3):139-144
Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X_L
Lundqvist A; Nagata T; Kiessling R; Pisa P
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2002;55(1):2-13
Hyaluronic acid and chondroitin sulphate A rapidly promote differentiation of immature DC with upregulation of costimulatory and antigen-presenting molecules, and enhancement of NF-κB and protein kinase activity
Yang R; Yan Z; Chen F; Hansson GK; Kiessling R
Journal article: JOURNAL OF ENVIRONMENTAL PATHOLOGY, TOXICOLOGY AND ONCOLOGY. 2002;21(4):54-330
Escape mechanisms in tumor immunity: an update.
Müller L; Kiessling R; Rees RC; Pawelec G
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2001;31(12):3602-3611
The identification of a common pathogen-specific HLA class I A*0201-restricted cytotoxic T cell epitope encoded within the heat shock protein 65
Charo J; Geluk A; Sundbäck M; Mirzai B; Diehl AD; Malmberg KJ; Achour A; Huriguchi S; van Meijgaarden KE; Drijfhout JW; Beekman N; van Veelen P; Ossendorp F; Ottenhoff THM; Kiessling R
Article: HUMAN GENE THERAPY. 2001;12(14):1797-1804
DNA immunization of HLA transgenic mice with a plasmid expressing mycobacterial heat shock protein 65 results in HLA class I- and II-restricted T cell responses that can be augmented by cytokines
Charo J; Sundbäck M; Geluk A; Ottenhoff T; Kiessling R
Journal article: EUROPEAN JOURNAL OF CANCER. 2001;37:s19
Specific vaccination based on the Her2/neu proto-oncogene
Kiessling R; Lindencrona J-A; Charo J; Hising C; Masucci G; Petersson M; Bergh J; Franksson L
Article: JOURNAL OF IMMUNOLOGY. 2001;167(5):2595-2601
Inhibition of activated/memory (CD45RO⁺) T cells by oxidative stress associated with block of NF-κB activation
Malmberg KJ; Arulampalam V; Ichihara F; Petersson M; Seki K; Andersson T; Lenkei R; Masucci G; Pettersson S; Kiessling R
Article: INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE. 2001;42(10):2153-2156
Association of HLA class I and class II antigen expression and mortality in uveal melanoma
Ericsson C; Seregard S; Bartolazzi A; Levitskaya E; Ferrone S; Kiessling R; Larsson O
Article: BLOOD. 2001;98(4):1108-1115
Tumor necrosis factor-α induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface
Hallermalm K; Seki K; Wei CH; Castelli C; Rivoltini L; Kiessling R; Levitskaya J
Article: JOURNAL OF CELL SCIENCE. 2001;114(2):423-433
Laminin-8 (α4β1γ1) is synthesized by lymphoid cells, promotes lymphocyte migration and costimulates T cell proliferation
Geberhiwot T; Assefa D; Kortesmaa J; Ingerpuu S; Pedraza C; Wondimu Z; Charo J; Kiessling R; Virtanen I; Tryggvason K; Patarroyo M
Article: CANCER RESEARCH. 2001;61(1):222-227
Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells
Castelli C; Ciupitu AMT; Rini F; Rivoltini L; Mazzocchi A; Kiessling R; Parmiani G
Journal article: BLOOD. 2000;96(9):3086-3093
The human antimicrobial and chemotactic peptides LL-37 and α-defensins are expressed by specific lymphocyte and monocyte populations
Agerberth B; Charo J; Werr J; Olsson B; Idali F; Lindbom L; Kiessling R; Jörnvall H; Wigzell H; Gudmundsson GH
Article: BLOOD. 2000;96(9):3086-3093
The human antimicrobial and chemotactic peptides LL-37 and α-defensins are expressed by specific lymphocyte and monocyte populations
Agerberth B; Charo J; Werr J; Olsson B; Idali F; Lindbom L; Kiessling R; Jörnvall H; Wigzell H; Gudmundsson GH
Article: HYPERTENSION. 2000;36(2):303-307
Circulating heat shock protein 60 is associated with early cardiovascular disease
Pockley AG; Wu R; Lemne C; Kiessling R; de Faire U; Frostegård J
Article: INTERNATIONAL JOURNAL OF CANCER. 2000;87(3):349-359
HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Article: JOURNAL OF IMMUNOLOGY. 2000;165(1):25-33
T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity
Sandberg JK; Franksson L; Sundbäck J; Michaelsson J; Petersson M; Achour A; Wallin RPA; Sherman NE; Bergman T; Jörnvall H; Hunt DF; Kiessling R; Kärre K
Article: JOURNAL OF IMMUNOLOGY. 1999;163(11):5913-5919
A long-term memory obtained by genetic immunization results in full protection from a mammary adenocarcinoma expressing an EBV gene
Charo J; Ciupitu AMT; de Préville AL; Trivedi P; Klein G; Hinkula J; Kiessling R
Article: JOURNAL OF IMMUNOLOGY. 1999;163(8):4207-4212
NK cell triggering by the human costimulatory molecules CD80 and CD86
Wilson JL; Charo J; Martín-Fontecha A; Dellabona P; Casorati G; Chambers BJ; Kiessling R; Bejarano MT; Ljunggren HG
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 1999;48(7):353-362
Tumor-induced immune dysfunction
Kiessling R; Wasserman K; Horiguchi S; Kono K; Sjöberg J; Pisa P; Petersson M
Article: JOURNAL OF IMMUNOLOGY. 1999;163(2):1037-1044
Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas
Yang RC; Salazar-Onfray F; Charo J; Malmberg KJ; Evrin K; Maes H; Kono K; Hising C; Petersson M; Larsson O; Lan L; Appella E; Sette A; Celis E; Kiessling R
Article: CANCER RESEARCH. 1999;59(12):2950-2956
Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells
Horiguchi S; Petersson M; Nakazawa T; Kanda M; Zea AH; Ochoa AC; Kiessling R
Article: IMMUNOLOGY LETTERS. 1999;67(3):243-249
Generation and function of bone marrow-derived dendritic cells from CD4/CD8^-/- double-knockout mice
Corsi MM; Sandberg JK; Wasserman K; Maes HH; Kiessling R
Article: INTERNATIONAL JOURNAL OF CANCER. 1998;78(2):202-208
Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes
Kono K; Yang RC; Charo J; Ichihara F; Celis E; Sette A; Appella E; Sekikawa T; Matsumoto Y; Kiessling R
Article: MELANOMA RESEARCH. 1998;8(5):389-397
Expression of the insulin-like growth factor-1 receptor and its anti-apoptotic effect in malignant melanoma: a potential therapeutic target
Kanter-Lewensohn L; Dricu A; Wang M; Wejde J; Kiessling R; Larsson O
Article: CYTOKINE. 1998;10(10):747-755
Interferon γ impairs the ability of monocyte-derived dendritic cells to present tumour-specific and allo-specific antigens and reduces their expression of CD1A, CD80 and CD4
Yang RC; Maes H; Corsi M; Dellner F; Tao W; Kiessling R
Article: JOURNAL OF IMMUNOLOGY. 1998;161(5):2099-2105
Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1
Petersson M; Charo J; Salazar-Onfray F; Noffz G; Mohaupt M; Qin ZH; Klein G; Blankenstein T; Kiessling R
Journal article: JOURNAL OF IMMUNOTHERAPY. 1998;21(4):317-322
PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCRζ expression but are functionally impaired
Nieland JD; Loviscek K; Kono K; Albain KS; McCall AR; Potkul RK; Fisher SG; Velders MP; Petersson M; Kiessling T; Kast WM
Article: JOURNAL OF EXPERIMENTAL MEDICINE (JEM). 1998;187(5):685-691
Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes
Ciupitu AMT; Petersson M; O'Donnell CL; Williams K; Jindal S; Kiessling R; Welsh RM
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1998;47(3):254-262
Decreased expression of signal-transducing CD3 ζ chains in T cells from the joints and peripheral blood of rheumatoid arthritis patients
Matsuda M; Ulfgren AK; Lenkei R; Petersson M; Ochoa AC; Lindblad S; Andersson P; Klareskog L; Kiessling R
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1997;94(21):11496-11501
Generation of CD8(+) T cells specific for transporter associated with antigen processing deficient cells
Wolpert EZ; Petersson M; Chambers BJ; Sandberg JK; Kiessling R; Ljunggren HG; Karre K
Article: CANCER RESEARCH. 1997;57(19):4348-4355
Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells
SalazarOnfray F; Nakazawa T; Chhajlani V; Petersson M; Karre K; Masucci G; Celis E; Sette A; Southwood S; Appella E; Kiessling R
Article: JOURNAL OF IMMUNOLOGY. 1997;159(7):3195-3202
Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10
SalazarOnfray F; Charo J; Petersson M; Freland S; Noffz G; Qin ZH; Blankenstein T; Ljunggren HG; Kiessling R
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1997;27(8):1988-1993
CD28 is not required for rejection of unmanipulated syngeneic and autologous tumors
Wen T; Kono K; Shahinian A; Kiessling R; Mak TW; Klein G
Article: STEM CELLS AND DEVELOPMENT. 1997;6(3):253-260
Efficient harvest of in vivo IL-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective leukapheresis (lymphocytapheresis)
Masucci G; Svensson A; Hansson M; Hansson J; Nakazawa T; Salazar F; Petersson M; Kiessling R
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1997;45(6):678-682
Conversion of in vitro cultured human monocytes into effective presenters of an HER2/neu-encoded CTL peptide epitope
Wasserman K; Corsi MM; Szekely L; Kono K; Maes HH; Kiessling R
Journal article: IMMUNOLOGY LETTERS. 1997;56:378
Using hsp70 as carrier of antigenic peptides
Ciupitu A-MT; Petersson M; Kono K; Kiessling R
Journal article: IMMUNOLOGY LETTERS. 1997;56:361
Signal transducing zeta chain analysis in peripheral T cells of animals and patients with various (pre) cancerous lesions
Nieland JD; Loviscek K; Albain K; McCall A; Potkul RK; Kono K; Petersson M; Kiessling R; Kast WM
Journal article: IMMUNOLOGY LETTERS. 1997;56:214
CTL-mediated immunity against human papillomavirus type 16 E7-encoded epitopes presented by HLA-A2
Ressing ME; Brandt RMP; de Jong JH; Kono K; Kiessling R; Potkul RK; Kenter G; Trimbos JB; Offringa R; Kast WM; Melief CJM
Article: INTERNATIONAL JOURNAL OF CANCER. 1997;70(1):112-119
Mechanisms of escape from CD8(+) T-cell clones specific for the HER-2/neu proto-oncogene expressed in ovarian carcinomas: Related and unrelated to decreased MHC class 1 expression
Kono K; Halapi E; Hising C; Petersson M; Gerdin E; Vanky F; Kiessling R
Article: HYPERTENSION. 1997;29(1):40-44
Association of serum antibodies to heat-shock protein 65 with borderline hypertension
Frostegard J; Lemne C; Andersson B; vanderZee R; Kiessling R; deFaire U
Article: CLINICAL CANCER RESEARCH. 1996;2(11):1825-1828
Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer
Kono K; Ressing ME; Brandt RMP; Melief CJM; Potkul RK; Andersson B; Petersson M; Kast WM; Kiessling R
Article: INFECTION AND IMMUNITY. 1996;64(10):4356-4358
Induction of heat shock protein 60 expression in human monocytic cell lines infected with Mycobacterium leprae
Beimnet K; Soderstrom K; Jindal S; Gronberg A; Frommel D; Kiessling R
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1996;26(6):1308-1313
Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity
Kono K; SalazarOnfray F; Petersson M; Hansson J; Masucci G; Wasserman K; Nakazawa T; Anderson P; Kiessling R
Article: JOURNAL OF IMMUNOLOGY. 1996;156(6):2331-2339
Increased frequency of abnormal gamma delta T cells in blood of patients with inflammatory bowel diseases
Soderstrom K; Bucht A; Halapi E; Gronberg A; Magnusson I; Kiessling R
Article: ATHEROSCLEROSIS. 1996;121(1):93-103
Induction of heat shock protein in monocytic cells by oxidized low density lipoprotein
Frostegard J; Kjellman B; Gidlund M; Andersson B; Jindal S; Kiessling R
Article: SEMINARS IN IMMUNOPATHOLOGY. 1996;18(2):227-242
Immunosuppression in human tumor-host interaction: Role of cytokines and alterations in signal-transducing molecules
Kiessling R; Kono K; Petersson M; Wasserman K
Article: CANCER RESEARCH. 1995;55(23):5648-5655
METHYLCHOLANTHRENE-INDUCED MOUSE SARCOMAS EXPRESS INDIVIDUALLY DISTINCT MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I-ASSOCIATED PEPTIDES RECOGNIZED BY SPECIFIC CD8+ T-CELL LINES
KONO K; PETERSSON M; CIUPITU AMT; WEN T; KLEIN G; KIESSLING R
Article: INTERNATIONAL JOURNAL OF CANCER. 1995;63(3):366-371
LACK OF INTERLEUKIN-2 (IL-2) EXPRESSION AND SELECTIVE EXPRESSION OF IL-10 MESSENGER-RNA IN HUMAN RENAL-CELL CARCINOMA
NAKAGOMI H; PISA P; PISA EK; YAMAMOTO Y; HALAPI E; BACKLIN K; JUHLIN C; KIESSLING R
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1995;42(1):34-38
ENGAGEMENT OF MHC CLASS-I PROTEINS ON NATURAL-KILLER-CELLS INHIBITS THEIR KILLING CAPACITY
PETERSSON MGE; GRONBERG A; KIESSLING R; FERM MT
Article: JOURNAL OF IMMUNOLOGY. 1995;154(12):6291-6298
IL-10 CONVERTS MOUSE LYMPHOMA-CELLS TO A CTL-RESISTANT, NK-SENSITIVE PHENOTYPE WITH LOW BUT PEPTIDE-INDUCIBLE MHC CLASS-I EXPRESSION
SALAZARONFRAY F; PETERSSON M; FRANKSSON L; MATSUDA M; BLANKENSTEIN T; KARRE K; KIESSLING R
Article: INTERNATIONAL JOURNAL OF CANCER. 1995;61(6):765-772
ALTERATIONS IN THE SIGNAL-TRANSDUCING MOLECULES OF T-CELLS AND NK CELLS IN COLORECTAL TUMOR-INFILTRATING, GUT MUCOSAL AND PERIPHERAL LYMPHOCYTES - CORRELATION WITH THE STAGE OF THE DISEASE
MATSUDA M; PETERSSON M; LENKEI R; TAUPIN JL; MAGNUSSON I; MELLSTEDT H; ANDERSON P; KIESSLING R
Journal article: JOURNAL OF EXPERIMENTAL MEDICINE (JEM). 1994;180(6):2371-2376
INTERLEUKIN-10 PRETREATMENT PROTECTS TARGET-CELLS FROM TUMOR-SPECIFIC AND ALLO-SPECIFIC CYTOTOXIC T-CELLS AND DOWN-REGULATES HLA CLASS-I EXPRESSION
MATSUDA M; SALAZAR F; PETERSSON M; MASUCCI G; HANSSON J; PISA P; ZHANG QJ; MASUCCI MG; KIESSLING R
Journal article: JOURNAL OF IMMUNOLOGY. 1994;152(12):6017-6027
HIGH EXPRESSION OF V-GAMMA-8 IS A SHARED FEATURE OF HUMAN GAMMA-DELTA T-CELLS IN THE EPITHELIUM OF THE GUT AND IN THE INFLAMED SYNOVIAL TISSUE
SODERSTROM K; BUCHT A; HALAPI E; LUNDQVIST C; GRONBERG A; NILSSON E; ORSINI DLM; VANDEWAL Y; KONING F; HAMMARSTROM ML; KIESSLING R
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1994;57(2):240-244
THE EPSTEIN-BARR-VIRUS LATENT MEMBRANE PROTEIN-1 (LMP1) INDUCES INTERLEUKIN-10 PRODUCTION IN BURKITT-LYMPHOMA LINES
NAKAGOMI H; DOLCETTI R; BEJARANO MT; PISA P; KIESSLING R; MASUCCI MG
Journal article: IMMUNOL SER. 1994;61:37-39
Antitumor effector cells: characteristics and basic mechanisms. Introduction.
Kiessling R
Journal article: CANCER RESEARCH. 1993;53(23):5610-5612
DECREASED EXPRESSION OF THE SIGNAL-TRANSDUCING ZETA-CHAINS IN TUMOR-INFILTRATING T-CELLS AND NK CELLS OF PATIENTS WITH COLORECTAL-CARCINOMA
NAKAGOMI H; PETERSSON M; MAGNUSSON I; JUHLIN C; MATSUDA M; MELLSTEDT H; TAUPIN JL; VIVIER E; ANDERSON P; KIESSLING R
Journal article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1993;23(10):2606-2613
IMMUNIZATION AGAINST TUMOR AND MINOR HISTOCOMPATIBILITY ANTIGENS BY ELUTED CELLULAR PEPTIDES LOADED ON ANTIGEN-PROCESSING DEFECTIVE CELLS
FRANKSSON L; PETERSSON M; KIESSLING R; KARRE K
Journal article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 1993;37(3):163-168
CYTOTOXIC ACTIVITY AND T-CELL RECEPTOR REPERTOIRE IN TUMOR-INFILTRATING LYMPHOCYTES OF ADRENAL-CELL CARCINOMAS
YAMAMOTO Y; BACKLIN K; NAKAGOMI H; HALAPI E; JUHLIN C; BUCHT A; KIESSLING R
Journal article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 1993;36(3):191-197
RESTRICTED T-CELL RECEPTOR V-BETA AND J-BETA USAGE IN T-CELLS FROM INTERLEUKIN-2-CULTURED LYMPHOCYTES OF OVARIAN AND RENAL CARCINOMAS
HALAPI E; YAMAMOTO Y; JUHLIN C; JEDDITEHRANI M; GRUNEWALD J; ANDERSSON R; HISING C; MASUCCI G; MELLSTEDT H; KIESSLING R
Journal article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1992;22(11):2879-2885
INTEGRINS AND OTHER ADHESION MOLECULES ON LYMPHOCYTES FROM SYNOVIAL-FLUID AND PERIPHERAL-BLOOD OF RHEUMATOID-ARTHRITIS PATIENTS
TAKAHASHI H; SODERSTROM K; NILSSON E; KIESSLING R; PATARROYO M
Journal article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1992;89(16):7708-7712
SELECTIVE EXPRESSION OF INTERLEUKIN-10, INTERFERON-GAMMA, AND GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR IN OVARIAN-CANCER BIOPSIES
PISA P; HALAPI E; PISA EK; GERDIN E; HISING C; BUCHT A; GERDIN B; KIESSLING R
Journal article: INTERNATIONAL IMMUNOLOGY. 1992;4(3):355-360
SOLUBLE CD4 SUPPRESS THE ANTIGEN DRIVEN PROLIFERATIVE RESPONSE OF CERTAIN T-CELL CLONES SPECIFIC FOR MYCOBACTERIA AND FOR PEPTIDES BY MYCOBACTERIAL HEAT-SHOCK PROTEINS
GIDLUND M; HALAPI E; CORNELISSE Y; OTTENHOF T; WIGZELL H; KIESSLING R
Journal article: INTERNATIONAL IMMUNOLOGY. 1992;4(3):305-311
INDUCTION OF HUMAN HSP60 EXPRESSION IN MONOCYTIC CELL-LINES
FERM MT; SODERSTROM K; JINDAL S; GRONBERG A; IVANYI J; YOUNG R; KIESSLING R
Journal article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1992;22(2):567-574
T-CELL RECEPTOR DIVERSITY AND ACTIVATION MARKERS IN THE V-DELTA-1 SUBSET OF RHEUMATOID SYNOVIAL-FLUID AND PERIPHERAL-BLOOD LYMPHOCYTES-T
BUCHT A; SODERSTROM K; HULTMAN T; UHLEN M; NILSSON E; KIESSLING R; GRONBERG A
Journal article: MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY. 1992;9(1):25-33
DIVERSE EFFECT OF CYTOKINE TREATMENT OF TUMOR-CELLS ON SPECIFIC VERSUS NONSPECIFIC CYTOTOXICITY
NAGANUMA H; HALAPI E; MASUCCI G; HANSSON M; WERSALL P; HISING C; VENKATESWARAN S; MELLSTEDT H; KIESSLING R
Journal article: TRENDS IN IMMUNOLOGY. 1991;12(10):343-345
MULTIPLE INTERACTIONS AT THE NATURAL-KILLER WORKSHOP
KARRE K; HANSSON M; KIESSLING R
Journal article: IMMUNOLOGICAL REVIEWS. 1991;121:91-111
ROLE OF HSP60 DURING AUTOIMMUNE AND BACTERIAL INFLAMMATION
KIESSLING R; GRONBERG A; IVANYI J; SODERSTROM K; FERM M; KLEINAU S; NILSSON E; KLARESKOG L
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1991;47(4):527-532
INCREASED SUSCEPTIBILITY OF IFN-GAMMA-TREATED NEUROBLASTOMA-CELLS TO LYSIS BY LYMPHOKINE-ACTIVATED KILLER-CELLS - PARTICIPATION OF ICAM-1 INDUCTION ON TARGET-CELLS
NAGANUMA H; KIESSLING R; PATARROYO M; HANSSON M; HANDGRETINGER R; GRONBERG A
Journal article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1991;33(2):195-202
A MONOCLONAL-ANTIBODY TO THE MYCOBACTERIAL 65KDA HEAT-SHOCK PROTEIN (ML-30) BINDS TO CELLS IN NORMAL AND ARTHRITIC JOINTS OF RATS
KLEINAU S; SODERSTROM K; KIESSLING R; KLARESKOG L
Journal article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1990;20(12):2651-2659
MYCOBACTERIAL-INDUCED CYTOTOXIC T-CELLS AS WELL AS NONSPECIFIC KILLER-CELLS DERIVED FROM HEALTHY-INDIVIDUALS AND LEPROSY PATIENTS
KALEAB B; OTTENOFF T; CONVERSE P; HALAPI E; TADESSE G; ROTTENBERG M; KIESSLING R
Journal article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1990;32(5):503-515
SYNOVIAL-CELLS RESPONDING TO A 65-KDA MYCOBACTERIAL HEAT-SHOCK PROTEIN HAVE A HIGH PROPORTION OF A TCR-GAMMA-DELTA SUBTYPE UNCOMMON IN PERIPHERAL-BLOOD
SODERSTROM K; HALAPI E; NILSSON E; GRONBERG A; VANEMBDEN J; KLARESKOG L; KIESSLING R
Journal article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1990;32(2):83-91
INTRADERMAL RECOMBINANT INTERLEUKIN-2 ENHANCES PERIPHERAL-BLOOD T-CELL RESPONSES TO MITOGEN AND ANTIGENS IN PATIENTS WITH LEPROMATOUS LEPROSY
CONVERSE P; OTTENHOFF THM; TEKLEMARIAM SW; HANCOCK GE; DIETZ M; BECXBLEUMINK M; WONDIMU A; KIESSLING R; COHN ZA; KAPLAN G
Journal article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1990;31(3):283-288
PRESENCE OF HUMAN 65 KD HEAT-SHOCK PROTEIN (HSP) IN INFLAMED JOINTS AND SUBCUTANEOUS NODULES OF RA PATIENTS
KARLSSONPARRA A; SODERSTROM K; FERM M; IVANYI J; KIESSLING R; KLARESKOG L
Journal article: JOURNAL OF INFECTIOUS DISEASES. 1990;161(5):988-991
SERUM TUMOR-NECROSIS-FACTOR LEVELS AND DISEASE DISSEMINATION IN LEPROSY AND LEISHMANIASIS
PISA P; GENNENE M; SODER O; OTTENHOFF T; HANSSON M; KIESSLING R
Journal article: TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE. 1990;84(3):359-362
THE VALUE OF A DIRECT AGGLUTINATION-TEST IN THE DIAGNOSIS OF CUTANEOUS AND VISCERAL LEISHMANIASIS IN ETHIOPIA
MENGISTU G; KIESSLING R; AKUFFO H
Journal article: JOURNAL OF INFECTIOUS DISEASES. 1990;161(4):775-780
ADMINISTRATION OF RECOMBINANT INTERLEUKIN-2 REDUCES THE LOCAL PARASITE LOAD OF PATIENTS WITH DISSEMINATED CUTANEOUS LEISHMANIASIS
AKUFFO H; KAPLAN G; KIESSLING R; TEKLEMARIAM S; DIETZ M; MCELRATH J; COHN ZA
Journal article: LAKARTIDNINGEN. 1990;87(13):1047-1053
[The gamma/delta T-cell: a first line help in bacterial infections or a dangerous autoimmune killer cell?].
Kiessling R
Journal article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1990;20(2):369-377
INDUCTION OF ANTIGEN-SPECIFIC CD4+ HLA-DR-RESTRICTED CYTOTOXIC LYMPHOCYTES-T AS WELL AS NONSPECIFIC NONRESTRICTED KILLER-CELLS BY THE RECOMBINANT MYCOBACTERIAL 65-KDA HEAT-SHOCK PROTEIN
KALE B; KIESSLING R; VANEMBDEN JDA; THOLE JER; KUMARARATNE DS; PISA P; WONDIMU A; OTTENHOFF THM
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1989;44(4):669-674
EFFECT OF IFN-GAMMA TREATMENT AND INVIVO PASSAGE OF MURINE TUMOR-CELL LINES ON THEIR SENSITIVITY TO LYMPHOKINE-ACTIVATED KILLER (LAK) CELL-LYSIS INVITRO - ASSOCIATION WITH H-2 EXPRESSION ON THE TARGET-CELLS
TSAI L; OHLEN C; LJUNGGREN HG; KARRE K; HANSSON M; KIESSLING R
Journal article: CELLULAR IMMUNOLOGY. 1989;118(1):10-21
INTERFERON IS ABLE TO REDUCE TUMOR-CELL SUSCEPTIBILITY TO HUMAN LYMPHOKINE-ACTIVATED KILLER (LAK) CELLS
GRONBERG A; FERM M; TSAI L; KIESSLING R
Journal article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1988;18(3):485-488
INVIVO FUNCTION OF NATURAL-KILLER CELLS AS REGULATORS OF MYELOID PRECURSOR CELLS IN THE SPLEEN
HANSSON M; PETERSSON M; KOO GC; WIGZELL H; KIESSLING R
Journal article: CELLULAR IMMUNOLOGY. 1987;108(2):460-472
AN ACTIVE T-CELL-INDEPENDENT MECHANISM ENHANCES MHC CLASS-I TRANSCRIPTION AND EXPRESSION ON A MOUSE T-CELL LYMPHOMA INVIVO
PETERSSON MGE; KARRE K; COCHET M; KOURILSKY P; KIESSLING R
Journal article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1987;84(10):3405-3409
INTERFERON-GAMMA INDUCES LUNG COLONIZATION BY INTRAVENOUSLY INOCULATED B-16 MELANOMA-CELLS IN PARALLEL WITH ENHANCED EXPRESSION OF CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX ANTIGENS
TANIGUCHI K; PETERSSON M; HOGLUND P; KIESSLING R; KLEIN G; KARRE K
Journal article: JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS. 1987;1(1):37-44
IFN-gamma is not the only mediator of suppressed myelopoiesis produced by mononuclear cells from aplastic anemia patients.
Laskay T; Hansson M; Porwit A; Björkholm M; Berthold W; Kiessling R
Journal article: JOURNAL OF IMMUNOLOGICAL METHODS. 1986;95(1):1-7
AN IMMUNOFLUORESCENT METHOD FOR IDENTIFYING INDIVIDUAL IFN-GAMMA-PRODUCING LYMPHOCYTES
LASKAY T; ANDERSSON U; ANDERSSON J; KIESSLING R; DELEY M
Journal article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1986;16(11):1457-1460
PHENOTYPIC CHARACTERIZATION OF INDIVIDUAL INTERFERON-GAMMA-PRODUCING CELLS AFTER OKT3-ANTIBODY ACTIVATION
ANDERSSON U; LASKAY T; ANDERSSON J; KIESSLING R; DELEY M
Journal article: JOURNAL OF VIROLOGY. 1986;59(2):428-433
MECHANISMS OF LYMPHOCYTIC CHORIOMENINGITIS VIRUS-INDUCED HEMATOPOIETIC DYSFUNCTION
THOMSEN AR; PISA P; BROJORGENSEN K; KIESSLING R
Journal article: NATURE. 1986;319(6055):675-678
SELECTIVE REJECTION OF H-2-DEFICIENT LYMPHOMA VARIANTS SUGGESTS ALTERNATIVE IMMUNE DEFENSE STRATEGY
KARRE K; LJUNGGREN HG; PIONTEK G; KIESSLING R
Journal article: ACTA PHARMACEUTICA SUECICA. 1986;23(2):91-100
STUDIES OF SWEDISH MARINE ORGANISMS .5. A SCREENING FOR LECTIN-LIKE ACTIVITY
ANDERSSON L; LIDGREN G; BOHLIN L; PISA P; WIGZELL H; KIESSLING R
Journal article: NATURAL IMMUNITY AND CELL GROWTH REGULATION. 1986;5(5):267-276
GENETIC-STUDIES ON A TUMOR GROWTH-INHIBITORY FACTOR IN SERUM OF NORMAL MICE AND ITS RELATIONSHIP TO NK ACTIVITY
GUEVARA LA; PETERSSON M; GRONBERG A; KIESSLING R
Journal article: NATURAL IMMUNITY AND CELL GROWTH REGULATION. 1986;5(4):211-220
INTERFERON AND BUTYRATE TREATMENT LEADS TO A DECREASED SENSITIVITY OF NK TARGET-CELLS TO LYSIS BY HOMOLOGOUS BUT NOT BY HETEROLOGOUS EFFECTOR-CELLS
LASKAY T; KIESSLING R
Journal article: JOURNAL OF IMMUNOLOGY. 1985;135(6):4281-4288
YAC-1 MHC CLASS-I VARIANTS REVEAL AN ASSOCIATION BETWEEN DECREASED NK SENSITIVITY AND INCREASED H-2 EXPRESSION AFTER INTERFERON TREATMENT OR INVIVO PASSAGE
PIONTEK GE; TANIGUCHI K; LJUNGGREN HG; GRONBERG A; KIESSLING R; KLEIN G; KARRE K
Journal article: CELLULAR IMMUNOLOGY. 1985;95(1):195-202
INTERFERON-GAMMA IS A STRONG MODULATOR OF NK SUSCEPTIBILITY AND EXPRESSION OF BETA-2-MICROGLOBULIN BUT NOT OF TRANSFERRIN RECEPTORS OF K562 CELLS
GRONBERG A; KIESSLING R; FIERS W
Journal article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 1985;74(1):67-75
COMPARISON BETWEEN MURINE NATURAL ANTIBODIES AND NATURAL-KILLER CELLS - RECOGNITION OF SEPARATE TARGET STRUCTURES AS REVEALED BY DIFFERENTIAL INVITRO EXPRESSION AND DEPENDENCE ON GLYCOSYLATION
GRONBERG A; ERIKSSON E; SINANGIL F; RONNHOLM M; FEIZI T; MINDEN P; KIESSLING R
Journal article: TOKAI JOURNAL OF EXPERIMENTAL AND CLINICAL MEDICINE. 1983;8(5-6):429-448
Genetic control of in vitro NK-activity and in vivo resistance to tumors.
Kärre K; Klein GO; Kiessling R; Klein G
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1983;32(5):609-616
GAMMA-INTERFERON (IFN-GAMMA) PRODUCED DURING EFFECTOR AND TARGET INTERACTIONS RENDERS TARGET-CELLS LESS SUSCEPTIBLE TO NK-CELL-MEDIATED LYSIS
GRONBERG A; KIESSLING R; MASUCCI G; GUEVARA LA; ERIKSSON E; KLEIN G
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1983;32(2):247-252
Incidence and type of tumors induced by DMBA carcinogenesis in H-2 congenic strains on a B10 background.
Grönberg A; Cochran AJ; Kärre K; Klein G; Klein GO; Kiessling R
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1983;31(4):501-507
INTERFERON-INDUCED INCREASE IN NEURAMINIDASE-RELEASABLE SIALIC-ACID AND GLYCOSPHINGOLIPID METABOLISM IN MOUSE LYMPHOMA AND L1210 LEUKEMIC-CELL LINES - CORRELATION WITH SUSCEPTIBILITY TO NATURAL-KILLER CELL-MEDIATED LYSIS
YOGEESWARAN G; GRONBERG A; WELSH RM; KIESSLING R
Journal article: BLOOD. 1983;61(3):596-599
Human Natural Killer Cells Can Inhibit Clonogenic Growth of Fresh Leukemic Cells
Beran M; Hansson M; Kiessling R
Journal article: BLOOD. 1983;61(3):596-599
HUMAN NATURAL-KILLER CELLS CAN INHIBIT CLONOGENIC GROWTH OF FRESH LEUKEMIC-CELLS
BERAN M; HANSSON M; KIESSLING R
Journal article: JOURNAL OF EXPERIMENTAL MEDICINE (JEM). 1983;157(2):385-403
ANOMALOUS THY-1+ KILLER CELLS IN ALLOGENEIC AND F-1-ANTI-PARENTAL MIXED LEUKOCYTE-CULTURE - RELATION TO NATURAL-KILLER CELLS AND ALLOSPECIFIC CYTO-TOXIC LYMPHOCYTES-T
KARRE K; SEELEY JK; ERIKSSON E; BURTON RC; KIESSLING R
Journal article: IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA. 1983;3(3):495-506
REACTIVITY OF NATURAL-KILLER CELLS AGAINST NORMAL TARGET-CELLS
HANSSON M; KIESSLING R
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1982;30(5):659-662
THYMUS INDEPENDENCE OF HYBRID RESISTANCE AGAINST A PANEL OF T-CELL LYMPHOMAS OF H-2B ORIGIN
KLEIN GO; KARRE K; KIESSLING R; KLEIN G
Journal article: VIROLOGY. 1982;121(2):363-371
INTERFERON-INDUCED ALTERATIONS IN SIALIC-ACID AND GLYCOCONJUGATES OF L-929 CELLS
YOGEESWARAN G; FUJINAMI R; KIESSLING R; WELSH RM
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1982;30(2):225-229
NK-PATTERNED BINDING EXPRESSED BY NON-NK MOUSE LEUKOCYTES
PIONTEK GE; GRONBERG A; AHRLUND-RICHTER L; KIESSLING R; HENGARTNER H
Journal article: JOURNAL OF IMMUNOLOGY. 1982;129(1):126-132
INHIBITION OF INVITRO GRANULOPOIESIS BY AUTOLOGOUS ALLOGENEIC HUMAN NK CELLS
HANSSON M; BERAN M; ANDERSSON B; KIESSLING R
Journal article: EUROPEAN JOURNAL OF CANCER AND CLINICAL ONCOLOGY. 1982;18(2):191-198
DECREASED SENSITIVITY OF IMMUNOSELECTED AND NK-SELECTED YAC LYMPHOMA SUBLINES TO HYBRID RESISTANCE INVIVO
KLEIN GO; GRONBERG A; KIESSLING R; KLEIN G
Journal article: EUROPEAN JOURNAL OF CANCER AND CLINICAL ONCOLOGY. 1982;18(2):183-190
HYBRID RESISTANCE AGAINST A NATURAL-KILLER (NK) CELL-RESISTANT LYMPHOMA (YWA) IS MEDIATED BY A T-CELL-DEPENDENT MECHANISM
GRONBERG A; KLEIN GO; KARRE K; KIESSLING R; KLEIN G
Journal article: ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. 1982;146:367-374
CELL-SURFACE PROPERTIES INFLUENCING TARGET-CELL SENSITIVITY FOR NK-LYSIS
KIESSLING R; GRONBERG A
Journal article: LAKARTIDNINGEN. 1981;78(46):4131-4134
[Natural killer cells - a control mechanism against abnormal cells].
Kiessling R; Kärre K
Journal article: JOURNAL OF IMMUNOLOGY. 1981;127(5):1734-1739
VARIANTS FROM A MLV-INDUCED LYMPHOMA SELECTED FOR DECREASED SENSITIVITY TO NK LYSIS
GRONBERG A; KIESSLING R; ERIKSSON E; HANSSON M
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1981;28(4):517-526
CORRELATION OF GLYCOSPHINGOLIPIDS AND SIALIC-ACID IN YAC-1 LYMPHOMA VARIANTS WITH THEIR SENSITIVITY TO NATURAL KILLER-CELL-MEDIATED LYSIS
YOGEESWARAN G; GRONBERG A; HANSSON M; DALIANIS T; KIESSLING R; WELSH RM
Journal article: JOURNAL OF IMMUNOLOGY. 1981;126(1):219-225
INTERFERON-MEDIATED PROTECTION OF NORMAL AND TUMOR TARGET-CELLS AGAINST LYSIS BY MOUSE NATURAL-KILLER CELLS
WELSH RM; KARRE K; HANSSON M; KUNKEL LA; KIESSLING RW
Journal article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1981;11(1):8-12
HUMAN-FETAL THYMUS AND BONE-MARROW CONTAIN TARGET-CELLS FOR NATURAL-KILLER CELLS
HANSSON M; KIESSLING R; ANDERSSON B
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1980;26(6):789-797
INVITRO NK-ACTIVITY AND INVIVO RESISTANCE TO LEUKEMIA - STUDIES OF BEIGE, BEIGE-NUDE AND WILD-TYPE HOSTS ON C57BL BACKGROUND
KARRE K; KLEIN GO; KIESSLING R; KLEIN G; RODER JC
Journal article: JOURNAL OF IMMUNOLOGY. 1980;125(5):2225-2231
EFFECT OF INTERFERON AND INTERFERON INDUCERS ON THE NK SENSITIVITY OF NORMAL MOUSE THYMOCYTES
HANSSON M; KIESSLING R; ANDERSSON B; WELSH RM
Journal article: JOURNAL OF IMMUNOLOGY. 1980;125(4):1551-1557
A COMPARATIVE-ANALYSIS OF THE CELL-SURFACE PROPERTIES OF ACTIVATED VS ENDOGENOUS MOUSE NATURAL-KILLER CELLS
KIESSLING R; ERIKSSON E; HALLENBECK LA; WELSH RM
Journal article: JOURNAL OF IMMUNOGENETICS. 1980;7(5):401-407
THE GENETIC-REGULATION OF NK-ACTIVITY - STUDIES ON CONGENIC MICE WITH B-10 OR AKR BACKGROUND
KLEIN GO; KARRE K; KLEIN G; KIESSLING R
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1980;25(5):611-615
Killing of normal cells by activated mouse natural killer cells: evidence for two patterns of genetic regulation of lysis.
Kiessling RW; Welsh RM
Journal article: IMMUNOLOGY. 1980;40(1):107-116
TARGET-EFFECTOR CELL-INTERACTION IN THE NATURAL-KILLER CELL SYSTEM .5. ENERGY-REQUIREMENTS, MEMBRANE INTEGRITY, AND THE POSSIBLE INVOLVEMENT OF LYSOSOMAL-ENZYMES
RODER JC; ARGOV S; KLEIN M; PETERSSON C; KIESSLING R; ANDERSSON K; HANSSON M
Journal article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 1980;64(5):1113-1119
DEMONSTRATION OF NATURAL ANTIBODIES IN NORMAL RABBIT SERUM WITH SIMILAR SPECIFICITY PATTERN AS MOUSE NATURAL-KILLER CELLS
GRONBERG A; HANSSON M; KLESSLING R; ANDERSSON B; KARRE K; RODER J
Journal article: NATURE. 1980;284(5757):624-626
LOW NATURAL INVIVO RESISTANCE TO SYNGENEIC LEUKEMIAS IN NATURAL KILLER-DEFICIENT MICE
KARRE K; KLEIN GO; KIESSLING R; KLEIN G; RODER JC
Journal article: JOURNAL OF IMMUNOLOGY. 1979;123(2):765-771
NATURAL NK-CELL TARGETS IN THE MOUSE THYMUS - CHARACTERISTICS OF THE SENSITIVE CELL-POPULATION
HANSSON M; KARRE K; KIESSLING R; RODER J; ANDERSSON B; HAYRY P
Journal article: BIOMEDICINE / [PUBLIEE POUR L'A.A.I.C.I.G.]. 1979;31(3):62-66
APPARENT IDENTITY OF MECHANISMS OF GENETIC-RESISTANCE TO MARROW TRANSPLANTATION AND NATURAL KILLER CELL-ACTIVITY
DATTA SK; GALLAGHER MT; TRENTIN JJ; KIESSLING R; WIGZELL H
Journal article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1979;9(4):283-288
FUNCTIONAL COMPARISON OF TUMOR-CELL KILLING BY ACTIVATED MACROPHAGES AND NATURAL KILLER CELLS
RODER JC; LOHMANNMATTHES ML; DOMZIG W; KIESSLING R; HALLER O
Journal article: NATURE. 1979;278(5700):174-176
NK CELL-SENSITIVE T-CELL SUB-POPULATION IN THYMUS - INVERSE CORRELATION TO HOST NK ACTIVITY
HANSSON M; KIESSLING R; ANDERSSON B; KARRE K; RODER J
Journal article: IMMUNOLOGICAL REVIEWS. 1979;44:165-208
ANALYSIS OF THE MURINE NK-CELL AS TO STRUCTURE, FUNCTION AND BIOLOGICAL RELEVANCE
KIESSLING R; WIGZELL H
Journal article: IMMUNOGENETICS. 1978;6(6):561-569
H-2-ASSOCIATED CONTROL OF NATURAL CYTOTOXICITY AND HYBRID RESISTANCE AGAINST RBL-5
KLEIN GO; KLEIN G; KIESSLING R; KARRE K
Journal article: IMMUNOGENETICS. 1978;7(5):391-404
HYBRID RESISTANCE AGAINST PARENTAL TUMORS - ONE OR SEVERAL GENETIC PATTERNS
KLEIN G; KLEIN GO; KARRE K; KIESSLING R
Journal article: JOURNAL OF IMMUNOLOGY. 1978;121(6):2509-2517
TARGET-EFFECTOR INTERACTION IN NATURAL KILLER (NK) CELL SYSTEM .2. ISOLATION OF NK-CELLS AND STUDIES ON MECHANISM OF KILLING
RODER JC; KIESSLING R; BIBERFELD P; ANDERSSON B
Journal article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 1978;61(6):1495-1498
MODULATION OF SENSITIVITY TO NATURAL KILLER CELL-LYSIS AFTER INVITRO EXPLANTATION OF A MOUSE LYMPHOMA
BECKER S; KIESSLING R; LEE N; KLEIN G
Journal article: JOURNAL OF IMMUNOLOGY. 1978;121(1):6-12
INTRASPECIES AND INTERSPECIES REACTIVITY OF HUMAN AND MOUSE NATURAL KILLER (NK) CELLS
HANSSON M; KARRE K; BAKACS T; KIESSLING R; KLEIN G
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1978;21(4):460-465
MOUSE NATURAL KILLER (NK) CELL ACTIVITY AGAINST HUMAN CELL LINES IS NOT INFLUENCED BY SUPER-INFECTION OF TARGET-CELL WITH XENOTROPIC MURINE C-TYPE VIRUS
KIESSLING R; HALLER O; FENYO EM; STEINITZ M; KLEIN G
Journal article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1978;8(2):135-144
TARGET-EFFECTOR INTERACTION IN NATURAL KILLER CELL SYSTEM .1. COVARIANCE AND GENETIC-CONTROL OF CYTOLYTIC AND TARGET-CELL BINDING SUB-POPULATIONS IN MOUSE
RODER JC; KIESSLING R
Journal article: NATURE. 1977;270(5638):609-611
ROLE OF NON-CONVENTIONAL NATURAL KILLER CELLS IN RESISTANCE AGAINST SYNGENEIC TUMOR-CELLS INVIVO
HALLER O; HANSSON M; KIESSLING R; WIGZELL H
Journal article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1977;7(9):655-663
EVIDENCE FOR A SIMILAR OR COMMON MECHANISM FOR NATURAL KILLER CELL ACTIVITY AND RESISTANCE TO HEMATOPOIETIC GRAFTS
KIESSLING R; HOCHMAN PS; HALLER O; SHEARER GM; WIGZELL H; CUDKOWICZ G
Journal article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1977;7(8):554-558
GENETIC-VARIATION IN ANTIBODY-RESPONSE AND NATURAL KILLER CELL ACTIVITY AGAINST A MOLONEY VIRUS-INDUCED LYMPHOMA (YAC)
ASJO B; KIESSLING R; KLEIN G; POVEY S
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1977;20(1):93-103
NATURAL CYTOTOXICITY TO HUMAN LEUKEMIA MEDIATED BY MOUSE NON-T CELLS
HALLER O; KIESSLING R; ORN A; KARRE K; NILSSON K; WIGZELL H
Journal article: JOURNAL OF EXPERIMENTAL MEDICINE (JEM). 1977;145(5):1411-1416
GENERATION OF NATURAL KILLER CELLS - AUTONOMOUS FUNCTION OF BONE-MARROW
HALLER O; KIESSLING R; ORN A; WIGZELL H
Journal article: IMMUNOGENETICS. 1976;3(1):15-28
GENETIC-CONTROL OF NATURAL KILLER CELL ACTIVITY AND ITS ASSOCIATION WITH INVIVO RESISTANCE AGAINST A MOLONEY LYMPHOMA ISOGRAFT
PETRANYI GG; KIESSLING R; POVEY S; KLEIN G; HERZENBERG L; WIGZELL H
Journal article: JOURNAL OF EXPERIMENTAL MEDICINE (JEM). 1976;143(4):772-780
KILLER CELLS - FUNCTIONAL COMPARISON BETWEEN NATURAL, IMMUNE T-CELL AND ANTIBODY-DEPENDENT INVITRO SYSTEMS
KIESSLING R; PETRANYI G; KARRE K; JONDAL M; TRACEY D; WIGZELL H
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1976;17(2):275-281
NON-T-CELL RESISTANCE AGAINST A MOUSE MOLONEY LYMPHOMA
KIESSLING R; PETRANYI G; KLEIN G; WIGZELL H
Journal article: IMMUNOGENETICS. 1975;2(1):53-61
GENETIC-CONTROL OF NATURAL KILLER LYMPHOCYTES IN MOUSE
PETRANYI GG; KIESSLING R; KLEIN G
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1975;15(6):933-940
GENETIC-VARIATION OF INVITRO CYTOLYTIC ACTIVITY AND INVIVO REJECTION POTENTIAL OF NON-IMMUNIZED SEMI-SYNGENEIC MICE AGAINST A MOUSE LYMPHOMA LINE
KIESSLING R; PETRANYI G; KLEIN G; WIGZELL H
Journal article: CANCER RESEARCH. 1975;35(4):962-969
COMPARISON OF ALLOSPECIFIC AND VIRAL-SPECIFIC IMMUNE-RESPONSES TO IRRADIATED VERSUS FORMALDEHYDE-FIXED ALLOGENEIC MOLONEY LYMPHOMA-CELLS IN CBA MICE
LAMON EW; GATTI RA; KIESSLING R; FENYO EM
Journal article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1975;5(2):117-121
NATURAL KILLER CELLS IN MOUSE .2. CYTOTOXIC CELLS WITH SPECIFICITY FOR MOUSE MOLONEY LEUKEMIA-CELLS - CHARACTERISTICS OF KILLER CELL
KIESSLING R; KLEIN E; PROSS H; WIGZELL H
Journal article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1975;5(2):112-117
NATURAL KILLER CELLS IN MOUSE .1. CYTOTOXIC CELLS WITH SPECIFICITY FOR MOUSE MOLONEY LEUKEMIA-CELLS - SPECIFICITY AND DISTRIBUTION ACCORDING TO GENOTYPE
KIESSLING R; KLEIN E; WIGZELL H
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1974;14(5):642-648
The lymphocyte response to primary Moloney sarcoma virus tumors: definition of a non-specific component of the in vitro cellular hyporeactivity of tumor-bearing hosts.
Kiessling R; Bataillon G; Lamon EW; Klein E
Journal article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 1973;51(5):1431-1436
Migration-inhibiting effect of sera from patients with Burkitt's lymphoma.
Cochran AJ; Klein G; Kiessling R; Gunvén P
Journal article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 1973;51(4):1109-1111
Human tumor cell migration.
Cochran AJ; Kiessling R; Klein E; Gunvén P; Foulis AK
Journal article: JOURNAL OF EXPERIMENTAL MEDICINE (JEM). 1973;137(2):527-532
Cytotoxic potential of mouse spleen cells on H-2 antibody-treated target cells.
Kiessling R; Klein E
Show more

All other publications

Letter: ACTA ONCOLOGICA. 2022;61(7):869-873
Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial
Backlund E; Yang M; Grozman V; Masucci G; Falkenius J; Eriksson H; Jovanovic B; Hammarlund K; Isacsson U; Radu C; Abel E; Karlsson K; Palanco Zamora R; Wersall P; Edback U; Wickstrom S; Darai Ramqvist E; Egyhazi Brage S; Kiessling R; Viktorsson K; Franzen B; Lewensohn R; Olofsson Bagge R; Ullenhag GJ; Ny L; Lindberg K; Helgadottir H
Review: ONCOGENE. 2021;40(2):421-435
Counteracting CAR T cell dysfunction
Poorebrahim M; Melief J; Pico de Coana Y; Wickstrom SL; Cid-Arregui A; Kiessling R
Review: PHARMACOLOGY AND THERAPEUTICS. 2020;214:107603
Genetically modified immune cells targeting tumor antigens
Poorebrahim M; Abazari MF; Sadeghi S; Mahmoudi R; Kheirollahi A; Askari H; Wickstrom SL; Poortahmasebi V; Lundqvist A; Kiessling R; Cid-Arregui A
Conference publication: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2019;7
Modulating BRD4 in T cells using self-delivery RNAi to improve adoptive cell therapy of cancer
Melief J; Kirsch LVL; Hemme E; Barrett J; Fricker S; Dispersyn G; Kiessling R
Conference publication: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2019;7
PD-1 checkpoint blockade in advanced melanoma patients: Neutrophils, NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates
de Coana YP; Wolodarski M; Avila IVDH; Nakajima T; Rentouli S; Lundqvist A; Masucci G; Hansson J; Kiessling R
Conference publication: CANCER IMMUNOLOGY RESEARCH. 2018;6(9):a14
Surgical removal of metastatic lesions increases T-cell reactivity to tumor-associated antigens in stage III melanoma patients
de Coana YP; Gunnarsdottir FB; Wolodarski M; Brage SE; Masucci G; Hansson J; Kiessling R
Meeting abstract: CANCER IMMUNOLOGY RESEARCH. 2018;6(9):a77
Cripto-1 vaccination elicits protective immune response to metastatic breast cancer and breast cancer stem cells
Witt K; Ligtenberg MA; Conti L; Lanzardo S; Ruiu R; Tufvesson-Stiller H; Ostling J; Rolny C; Lladser A; Lundqvist A; Cavallo F; Kiessling R
Conference publication: CANCER RESEARCH. 2018;78(13):lb-116-lb-116
Myeloid derived suppressor cells and NK cells are correlated with clinical benefit and survival in advanced melanoma patients treated with PD-1 blocking antibodies nivolumab and pembrolizumab
De Coana YP; Wolodarski M; Avila IVDH; Masucci GV; Hansson J; Kiessling R
Conference publication: CANCER RESEARCH. 2018;78(13):ct032
Adoptive T cell transfer combined with DC vaccination in patients with metastatic melanoma
Wickstrom SL; Lovgren T; Wolodarski M; Edback U; Martell E; Markland K; Nystrom M; Lundqvist A; Jacobsson H; Hansson J; Masucci G; Tell R; Poschke I; Adamson L; Mattsson J; Kiessling R
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):334
Cripto-1 vaccination elicits protective immune response to metastatic breast cancer and breast CSC
Witt K; Ligtenberg MA; Conti L; Lanzardo S; Tufvesson-Stiller H; Ostling J; Rolny C; Lladser A; Lundqvist A; Cavallo F; Kiessling R
Conference publication: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2016;4(Suppl 1):82
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
Lundqvist A; van Hoef V; Zhang X; Wennerberg E; Lorent J; Witt K; Sanz LM; Liang S; Murray S; Larsson O; Kiessling R; Mao Y; Sidhom J-W; Bessell CA; Havel J; Schneck J; Chan TA; Sachsenmeier E; Woods D; Berglund A; Ramakrishnan R; Sodre A; Weber J; Zappasodi R; Li Y; Qi J; Wong P; Sirard C; Postow M; Newman W; Koon H; Velcheti V; Callahan MK; Wolchok JD; Merghoub T; Lum LG; Choi M; Thakur A; Deol A; Dyson G; Shields A; Haymaker C; Uemura M; Murthy R; James M; Wang D; Brevard J; Monaghan C; Swann S; Geib J; Cornfeld M; Chunduru S; Agrawal S; Yee C; Wargo J; Patel SP; Amaria R; Tawbi H; Glitza I; Woodman S; Hwu W-J; Davies MA; Hwu P; Overwijk WW; Bernatchez C; Diab A; Massarelli E; Segal NH; Ribrag V; Melero I; Gangadhar TC; Urba W; Schadendorf D; Ferris RL; Houot R; Morschhauser F; Logan T; Luke JJ; Sharfman W; Barlesi F; Ott PA; Mansi L; Kummar S; Salles G; Carpio C; Meier R; Krishnan S; McDonald D; Maurer M; Gu X; Neely J; Suryawanshi S; Levy R; Khushalani N; Wu J; Zhang J; Basher F; Rubinstein M; Bucsek M; Qiao G; MacDonald C; Hylander B; Repasky E; Chatterjee S; Daenthanasanmak A; Chakraborty P; Toth K; Meek M; Garrett-Mayer E; Nishimura M; Paulos C; Beeson C; Yu X; Mehrotra S; Zhao F; Evans K; Xiao C; Holtzhausen A; Hanks BA; Scharping N; Menk AV; Moreci R; Whetstone R; Dadey R; Watkins S; Ferris R; Delgoffe GM; Peled J; Devlin S; Staffas A; Lumish M; Rodriguez KP; Ahr K; Perales M; Giralt S; Taur Y; Pamer E; van den Brink MRM; Jenq R; Annels N; Pandha H; Simpson G; Mostafid H; Harrington K; Melcher A; Grose M; Davies B; Au G; Karpathy R; Shafren D; Ricca J; Merghoub T; Wolchok JD; Zamarin D; Batista L; Marliot F; Vasaturo A; Carpentier S; Poggionovo C; Frayssinet V; Fieschi J; Van den Eynde M; Pagès F; Galon J; Hermitte F; Smith SG; Nguyen K; Ravindranathan S; Koppolu B; Zaharoff D; Schvartsman G; Bassett R; McQuade JL; Haydu LE; Davies MA; Tawbi H; Glitza I; Kline D; Chen X; Fosco D; Kline J; Overacre A; Chikina M; Brunazzi E; Shayan G; Horne W; Kolls J; Ferris RL; Delgoffe GM; Bruno TC; Workman C; Vignali D; Adusumilli PS; Ansa-Addo EA; Li Z; Gerry A; Sanderson JP; Howe K; Docta R; Gao Q; Bagg EAL; Tribble N; Maroto M; Betts G; Bath N; Melchiori L; Lowther DE; Ramachandran I; Kari G; Basu S; Binder-Scholl G; Chagin K; Pandite L; Holdich T; Amado R; Zhang H; Glod J; Bernstein D; Jakobsen B; Mackall C; Wong R; Silk JD; Adams K; Hamilton G; Bennett AD; Brett S; Jing J; Quattrini A; Saini M; Wiedermann G; Gerry A; Jakobsen B; Binder-Scholl G; Brewer J; Duong M; Lu A; Chang P; Mahendravada A; Shinners N; Slawin K; Spencer DM; Foster AE; Bayle JH; Bergamaschi C; Ng SSM; Nagy B; Jensen S; Hu X; Alicea C; Fox B; Felber B; Pavlakis G; Chacon J; Yamamoto T; Garrabrant T; Cortina L; Powell DJ; Donia M; Kjeldsen JW; Andersen R; Westergaard MCW; Bianchi V; Legut M; Attaf M; Dolton G; Szomolay B; Ott S; Lyngaa R; Hadrup SR; Sewell AK; Svane IM; Fan A; Kumai T; Celis E; Frank I; Stramer A; Blaskovich MA; Wardell S; Fardis M; Bender J; Lotze MT; Goff SL; Zacharakis N; Assadipour Y; Prickett TD; Gartner JJ; Somerville R; Black M; Xu H; Chinnasamy H; Kriley I; Lu L; Wunderlich J; Robbins PF; Rosenberg S; Feldman SA; Trebska-McGowan K; Kriley I; Malekzadeh P; Payabyab E; Sherry R; Rosenberg S; Goff SL; Gokuldass A; Blaskovich MA; Kopits C; Rabinovich B; Lotze MT; Green DS; Kamenyeva O; Zoon KC; Annunziata CM; Hammill J; Helsen C; Aarts C; Bramson J; Harada Y; Yonemitsu Y; Helsen C; Hammill J; Mwawasi K; Denisova G; Bramson J; Giri R; Jin B; Campbell T; Draper LM; Stevanovic S; Yu Z; Weissbrich B; Restifo NP; Trimble CL; Rosenberg S; Hinrichs CS; Tsang K; Fantini M; Hodge JW; Fujii R; Fernando I; Jochems C; Heery C; Gulley J; Soon-Shiong P; Schlom J; Jing W; Gershan J; Blitzer G; Weber J; McOlash L; Johnson BD; Kiany S; Gangxiong H; Kleinerman ES; Klichinsky M; Ruella M; Shestova O; Kenderian S; Kim M; Scholler J; June CH; Gill S; Moogk D; Zhong S; Yu Z; Liadi I; Rittase W; Fang V; Dougherty J; Perez-Garcia A; Osman I; Zhu C; Varadarajan N; Restifo NP; Frey A; Krogsgaard M; Landi D; Fousek K; Mukherjee M; Shree A; Joseph S; Bielamowicz K; Byrd T; Ahmed N; Hegde M; Lee S; Byrd D; Thompson J; Bhatia S; Tykodi S; Delismon J; Chu L; Abdul-Alim S; Ohanian A; DeVito AM; Riddell S; Margolin K; Magalhaes I; Mattsson J; Uhlin M; Nemoto S; Villarroel PP; Nakagawa R; Mule JJ; Mailloux AW; Mata M; Nguyen P; Gerken C; DeRenzo C; Spencer DM; Gottschalk S; Mathieu M; Pelletier S; Stagg J; Turcotte S; Minutolo N; Sharma P; Tsourkas A; Powell DJ; Mockel-Tenbrinck N; Mauer D; Drechsel K; Barth C; Freese K; Kolrep U; Schult S; Assenmacher M; Kaiser A; Mullinax J; Hall M; Le J; Kodumudi K; Royster E; Richards A; Gonzalez R; Sarnaik A; Pilon-Thomas S; Nielsen M; Krarup-Hansen A; Hovgaard D; Petersen MM; Loya AC; Junker N; Svane IM; Rivas C; Parihar R; Gottschalk S; Rooney CM; Qin H; Nguyen S; Su P; Burk C; Duncan B; Kim B-H; Kohler ME; Fry T; Rao AA; Teyssier N; Pfeil J; Sgourakis N; Salama S; Haussler D; Richman SA; Nunez-Cruz S; Gershenson Z; Mourelatos Z; Barrett D; Grupp S; Milone M; Rodriguez-Garcia A; Robinson MK; Adams GP; Powell DJ; Santos J; Havunen R; Siurala M; Cervera-Carrascón V; Parviainen S; Antilla M; Hemminki A; Sethuraman J; Santiago L; Chen JQ; Dai Z; Wardell S; Bender J; Lotze MT; Sha H; Su S; Ding N; Liu B; Stevanovic S; Pasetto A; Helman SR; Gartner JJ; Prickett TD; Robbins PF; Rosenberg SA; Hinrichs CS; Bhatia S; Burgess M; Zhang H; Lee T; Klingemann H; Soon-Shiong P; Nghiem P; Kirkwood JM; Rossi JM; Sherman M; Xue A; Shen Y-W; Navale L; Rosenberg SA; Kochenderfer JN; Bot A; Veerapathran A; Gokuldass A; Stramer A; Sethuraman J; Blaskovich MA; Wiener D; Frank I; Santiago L; Rabinovich B; Fardis M; Bender J; Lotze MT; Waller EK; Li J-M; Petersen C; Blazar BR; Li J; Giver CR; Wang Z; Grossenbacher SK; Sturgill I; Canter RJ; Murphy WJ; Zhang C; Burger MC; Jennewein L; Waldmann A; Mittelbronn M; Tonn T; Steinbach JP; Wels WS; Williams JB; Zha Y; Gajewski TF; Williams LC; Krenciute G; Kalra M; Louis C; Gottschalk S; Xin G; Schauder D; Jiang A; Joshi N; Cui W; Zeng X; Menk AV; Scharping N; Delgoffe GM; Zhao Z; Hamieh M; Eyquem J; Gunset G; Bander N; Sadelain M; Askmyr D; Abolhalaj M; Lundberg K; Greiff L; Lindstedt M; Angell HK; Kim K-M; Kim S-T; Kim S; Sharpe AD; Ogden J; Davenport A; Hodgson DR; Barrett C; Lee J; Kilgour E; Hanson J; Caspell R; Karulin A; Lehmann P; Ansari T; Schiller A; Sundararaman S; Lehmann P; Hanson J; Roen D; Karulin A; Lehmann P; Ayers M; Levitan D; Arreaza G; Liu F; Mogg R; Bang Y-J; O’Neil B; Cristescu R; Friedlander P; Wassman K; Kyi C; Oh W; Bhardwaj N; Bornschlegl S; Gustafson MP; Gastineau DA; Parney IF; Dietz AB; Carvajal-Hausdorf D; Mani N; Velcheti V; Schalper K; Rimm D; Chang S; Levy R; Kurland J; Krishnan S; Ahlers CM; Jure-Kunkel M; Cohen L; Maecker H; Kohrt H; Chen S; Crabill G; Pritchard T; McMiller T; Pardoll D; Pan F; Topalian S; Danaher P; Warren S; Dennis L; White AM; D’Amico L; Geller M; Disis ML; Beechem J; Odunsi K; Fling S; Derakhshandeh R; Webb TJ; Dubois S; Conlon K; Bryant B; Hsu J; Beltran N; Müller J; Waldmann T; Duhen R; Duhen T; Thompson L; Montler R; Weinberg A; Kates M; Early B; Yusko E; Schreiber TH; Bivalacqua TJ; Ayers M; Lunceford J; Nebozhyn M; Murphy E; Loboda A; Kaufman DR; Albright A; Cheng J; Kang SP; Shankaran V; Piha-Paul SA; Yearley J; Seiwert T; Ribas A; McClanahan TK; Cristescu R; Mogg R; Ayers M; Albright A; Murphy E; Yearley J; Sher X; Liu XQ; Nebozhyn M; Lunceford J; Joe A; Cheng J; Plimack E; Ott PA; McClanahan TK; Loboda A; Kaufman DR; Forrest-Hay A; Guyre CA; Narumiya K; Delcommenne M; Hirsch HA; Deshpande A; Reeves J; Shu J; Zi T; Michaelson J; Law D; Trehu E; Sathyanaryanan S; Hodkinson BP; Hutnick NA; Schaffer ME; Gormley M; Hulett T; Jensen S; Ballesteros-Merino C; Dubay C; Afentoulis M; Reddy A; David L; Fox B; Jayant K; Agrawal S; Agrawal R; Jeyakumar G; Kim S; Kim H; Silski C; Suisham S; Heath E; Vaishampayan U; Vandeven N; Viller NN; O’Connor A; Chen H; Bossen B; Sievers E; Uger R; Nghiem P; Johnson L; Kao H-F; Hsiao C-F; Lai S-C; Wang C-W; Ko J-Y; Lou P-J; Lee T-J; Liu T-W; Hong R-L; Kearney SJ; Black JC; Landis BJ; Koegler S; Hirsch B; Gianani R; Kim J; He M-X; Zhang B; Su N; Luo Y; Ma X-J; Park E; Kim DW; Copploa D; Kothari N; doo Chang Y; Kim R; Kim N; Lye M; Wan E; Kim N; Lye M; Wan E; Kim N; Lye M; Wan E; Knaus HA; Berglund S; Hackl H; Karp JE; Gojo I; Luznik L; Hong HS; Koch SD; Scheel B; Gnad-Vogt U; Kallen K-J; Wiegand V; Backert L; Kohlbacher O; Hoerr I; Fotin-Mleczek M; Billingsley JM; Koguchi Y; Conrad V; Miller W; Gonzalez I; Poplonski T; Meeuwsen T; Howells-Ferreira A; Rattray R; Campbell M; Bifulco C; Dubay C; Bahjat K; Curti B; Urba W; Vetsika E-K; Kallergi G; Aggouraki D; Lyristi Z; Katsarlinos P; Koinis F; Georgoulias V; Kotsakis A; Martin NT; Aeffner F; Kearney SJ; Black JC; Cerkovnik L; Pratte L; Kim R; Hirsch B; Krueger J; Gianani R; Martínez-Usatorre A; Jandus C; Donda A; Carretero-Iglesia L; Speiser DE; Zehn D; Rufer N; Romero P; Panda A; Mehnert J; Hirshfield KM; Riedlinger G; Damare S; Saunders T; Sokol L; Stein M; Poplin E; Rodriguez-Rodriguez L; Silk A; Chan N; Frankel M; Kane M; Malhotra J; Aisner J; Kaufman HL; Ali S; Ross J; White E; Bhanot G; Ganesan S; Monette A; Bergeron D; Amor AB; Meunier L; Caron C; Morou A; Kaufmann D; Liberman M; Jurisica I; Mes-Masson A-M; Hamzaoui K; Lapointe R; Mongan A; Ku Y-C; Tom W; Sun Y; Pankov A; Looney T; Au-Young J; Hyland F; Conroy J; Morrison C; Glenn S; Burgher B; Ji H; Gardner M; Mongan A; Omilian AR; Conroy J; Bshara W; Angela O; Burgher B; Ji H; Glenn S; Morrison C; Mongan A; Obeid JM; Erdag G; Smolkin ME; Deacon DH; Patterson JW; Chen L; Bullock TN; Slingluff CL; Obeid JM; Erdag G; Deacon DH; Slingluff CL; Bullock TN; Loffredo JT; Vuyyuru R; Beyer S; Spires VM; Fox M; Ehrmann JM; Taylor KA; Korman AJ; Graziano RF; Page D; Sanchez K; Ballesteros-Merino C; Martel M; Bifulco C; Urba W; Fox B; Patel SP; De Macedo MP; Qin Y; Reuben A; Spencer C; Guindani M; Bassett R; Wargo J; Racolta A; Kelly B; Jones T; Polaske N; Theiss N; Robida M; Meridew J; Habensus I; Zhang L; Pestic-Dragovich L; Tang L; Sullivan RJ; Logan T; Khushalani N; Margolin K; Koon H; Olencki T; Hutson T; Curti B; Roder J; Blackmon S; Roder H; Stewart J; Amin A; Ernstoff MS; Clark JI; Atkins MB; Kaufman HL; Sosman J; Weber J; McDermott DF; Weber J; Kluger H; Halaban R; Snzol M; Roder H; Roder J; Asmellash S; Steingrimsson A; Blackmon S; Sullivan RJ; Wang C; Roman K; Clement A; Downing S; Hoyt C; Harder N; Schmidt G; Schoenmeyer R; Brieu N; Yigitsoy M; Madonna G; Botti G; Grimaldi A; Ascierto PA; Huss R; Athelogou M; Hessel H; Harder N; Buchner A; Schmidt G; Stief C; Huss R; Binnig G; Kirchner T; Sellappan S; Thyparambil S; Schwartz S; Cecchi F; Nguyen A; Vaske C; Hembrough T; Spacek J; Vocka M; Zavadova E; Skalova H; Dundr P; Petruzelka L; Francis N; Tilman RT; Hartmann A; Netikova I; Ballesteros-Merino C; Stump J; Tufman A; Berger F; Neuberger M; Hatz R; Lindner M; Sanborn RE; Handy J; Fox B; Bifulco C; Huber RM; Winter H; Reu S; Sun C; Xiao W; Tian Z; Arora K; Desai N; Kulkarni A; Rajurkar M; Rivera M; Deshpande V; Ting D; Tsai K; Nosrati A; Goldinger S; Hamid O; Algazi A; Tumeh P; Hwang J; Liu J; Chen L; Dummer R; Rosenblum M; Daud A; Tsao T-S; Ashworth-Sharpe J; Johnson D; Bhaumik S; Bieniarz C; Couto J; Farrell M; Ghaffari M; Habensus I; Hubbard A; Jones T; Kelly B; Kosmeder J; Lee C; Marner E; Meridew J; Polaske N; Racolta A; Uribe D; Zhang H; Zhang J; Zhang W; Zhu Y; Morrison L; Pestic-Dragovich L; Tang L; Tsujikawa T; Borkar RN; Azimi V; Kumar S; Thibault G; Mori M; El Rassi E; Clayburgh DR; Kulesz-Martin MF; Flint PW; Coussens LM; Villabona L; Masucci GV; Geiss G; Birditt B; Mei Q; Huang A; White AM; Eagan MA; Ignacio E; Elliott N; Dunaway D; Dennis L; Warren S; Beechem J; Dunaway D; Jung J; Merritt C; Sprague I; Webster P; Liang Y; Warren S; Beechem J; Wenthe J; Enblad G; Karlsson H; Essand M; Savoldo B; Dotti G; Höglund M; Brenner MK; Hagberg H; Loskog A; Bernett MJ; Moore GL; Hedvat M; Bonzon C; Chu S; Rashid R; Avery KN; Muchhal U; Desjarlais J; Hedvat M; Bernett MJ; Moore GL; Bonzon C; Rashid R; Chu S; Avery KN; Muchhal U; Desjarlais J; Kraman M; Kmiecik K; Allen N; Faroudi M; Zimarino C; Wydro M; Doody J; Srinivasa SP; Govindappa N; Reddy P; Dubey A; Periyasamy S; Adekandi M; Dey C; Joy M; van Loo PF; Veninga H; Shamsili S; Throsby M; Dolstra H; Bakker L; Alva A; Gschwendt J; Loriot Y; Bellmunt J; Feng D; Poehlein C; Powles T; Antonarakis ES; Drake CG; Wu H; Poehlein C; De Bono J; Bannerji R; Byrd J; Gregory G; Opat S; Shortt J; Yee AJ; Raje N; Thompson S; Balakumaran A; Kumar S; Rini BI; Choueiri TK; Mariani M; Albiges L; Haanen JB; Atkins MB; Larkin J; Schmidinger M; Magazzù D; di Pietro A; Motzer RJ; Borch TH; Andersen R; Kongsted P; Pedersen M; Nielsen M; Met Ö; Donia M; Svane IM; Boudadi K; Wang H; Vasselli J; Baughman JE; Wigginton J; Abdallah R; Ross A; Drake CG; Antonarakis ES; Canter RJ; Park J; Wang Z; Grossenbacher S; Luna JI; Withers S; Culp W; Chen M; Monjazeb A; Kent MS; Murphy WJ; Chandran S; Somerville R; Wunderlich J; Danforth D; Yang J; Sherry R; Klebanoff C; Goff S; Paria B; Sabesan A; Srivastava A; Rosenberg SA; Kammula U; Curti B; Richards J; Faries M; Andtbacka RHI; Grose M; Shafren D; Diaz LA; Le DT; Yoshino T; André T; Bendell J; Koshiji M; Zhang Y; Kang SP; Lam B; Jäger D; Bauer TM; Wang JS; Lee JK; Manji GA; Kudchadkar R; Kauh JS; Tang S; Laing N; Falchook G; Garon EB; Halmos B; Rina H; Leighl N; Lee SS; Walsh W; Dragnev K; Piperdi B; Rodriguez LP-A; Shinwari N; Wei Z; Gustafson MP; Maas ML; Deeds M; Armstrong A; Bornschlegl S; Peterson T; Steinmetz S; Gastineau DA; Parney IF; Dietz AB; Herzog T; Backes FJ; Copeland L; Del Pilar Estevez Diz M; Hare TW; Huh W; Kim B-G; Moore KM; Oaknin A; Small W; Tewari KS; Monk BJ; Kamat AM; Bellmunt J; Choueiri TK; Nam K; De Santis M; Dreicer R; Hahn NM; Perini R; Siefker-Radtke A; Sonpavde G; de Wit R; Witjes JA; Keefe S; Bajorin D; Kline J; Armand P; Kuruvilla J; Moskowitz C; Hamadani M; Ribrag V; Zinzani PL; Chlosta S; Thompson S; Balakumaran A; Bartlett N; Kyi C; Sabado R; Saenger Y; William L; Donovan MJ; Sacris E; Mandeli J; Salazar AM; Friedlander P; Bhardwaj N; Powderly J; Brody J; Nemunaitis J; Emens L; Luke JJ; Patnaik A; McCaffery I; Miller R; Laport G; Coveler AL; Smith DC; Grilley-Olson JE; Gajewski TF; Goel S; Gardai SJ; Law C-L; Means G; Manley T; Curti B; Marrone KA; Rosner G; Anagnostou V; Riemer J; Wakefield J; Zanhow C; Baylin S; Gitlitz B; Brahmer J; McDermott DF; Signoretti S; Li W; Schloss C; Michot J-M; Armand P; Ding W; Ribrag V; Christian B; Balakumaran A; Marinello P; Chlosta S; Zhang Y; Shipp M; Zinzani PL; Najjar YG; Lin; Butterfield LH; Tarhini AA; Davar D; Zarour H; Rush E; Sander C; Kirkwood JM; Fu S; Bauer T; Molineaux C; Bennett MK; Orford KW; Papadopoulos KP; Padda SK; Shah SA; Colevas AD; Narayanan S; Fisher GA; Supan D; Wakelee HA; Aoki R; Pegram MD; Villalobos VM; Liu J; Takimoto CH; Chao M; Volkmer J-P; Majeti R; Weissman IL; Sikic BI; Page D; Yu W; Conlin A; Ruzich J; Lewis S; Acheson A; Kemmer K; Perlewitz K; Moxon NM; Mellinger S; Bifulco C; Martel M; Koguchi Y; Fox B; Urba W; McArthur H; Pedersen M; Westergaard MCW; Borch TH; Nielsen M; Kongsted P; Juhler-Nøttrup T; Donia M; Svane IM; Desai J; Markman B; Sandhu S; Gan H; Friedlander ML; Tran B; Meniawy T; Lundy J; Colyer D; Ameratunga M; Norris C; Yang J; Li K; Wang L; Luo L; Qin Z; Mu S; Tan X; Song J; Millward M; Katz MHG; Bauer TW; Varadhachary GR; Acquavella N; Merchant N; Petroni G; Slingluff CL; Rahma OE; Rini BI; Powles T; Chen M; Song Y; Puhlmann M; Atkins MB; Sathyanaryanan S; Hirsch HA; Shu J; Deshpande A; Khattri A; Reeves J; Zi T; Brisson R; Harvey C; Michaelson J; Law D; Seiwert T; Shah J; Mateos MV; Matsumoto M; Blacklock H; Rocafiguera AO; Goldschmidt H; Iida S; Yehuda DB; Ocio E; Rodríguez-Otero P; Jagannath S; Lonial S; Kher U; Marinello P; San-Miguel J; Shah J; Lonial S; de Oliveira MR; Yimer H; Mateos MV; Rifkin R; Schjesvold F; Ocio E; Rodríguez-Otero P; San-Miguel J; Ghori R; Marinello P; Jagannath S; Spreafico A; Lee V; Ngan RKC; To KF; Ahn MJ; Ng QS; Hong R-L; Lin J-C; Swaby RF; Gause C; Saraf S; Chan ATC; Lam E; Tannir NM; Meric-Bernstam F; Vaishampayan U; Orford KW; Molineaux C; Gross M; MacKinnon A; Whiting S; Voss M; Yu EY; Wu H; Schloss C; Albertini MR; Ranheim EA; Hank JA; Zuleger C; McFarland T; Collins J; Clements E; Weber S; Weigel T; Neuman H; Hartig G; Mahvi D; Henry M; Gan J; Yang R; Carmichael L; Kim K; Gillies SD; Sondel PM; Subbiah V; Murthy R; Noffsinger L; Hendricks K; Bosch M; Lee JM; Lee M-H; Garon EB; Goldman JW; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin YQ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp K; Wallace WD; Zeng G; Elashoff DA; Sharma S; Dubinett SM; Bhardwaj N; Friedlander P; Pavlick AC; Ernstoff MS; Gastman B; Hanks B; Albertini MR; Luke JJ; Keler T; Davis T; Vitale LA; Sharon E; Danaher P; Morishima C; Cheever M; Fling S; Heery CR; Kim JW; Lamping E; Marte J; McMahon S; Cordes L; Fakhrejahani F; Madan R; Tsang K; Jochems C; Salazar R; Zhang M; Helwig C; Schlom J; Gulley JL; Li R; Amrhein J; Cohen Z; Champagne M; Kamat A; Aznar MA; Labiano S; Diaz-Lagares A; Esteller M; Sandoval J; Melero I; Barbee SD; Bellovin DI; Timmer JC; Wondyfraw N; Johnson S; Park J; Chen A; Mkrtichyan M; Razai AS; Jones KS; Hata CY; Gonzalez D; Deveraux Q; Eckelman BP; Borges L; Bhardwaj R; Puri RK; Suzuki A; Leland P; Joshi BH; Bartkowiak T; Jaiswal A; Ager C; Ai M; Budhani P; Chin R; Hong D; Curran M; Hastings WD; Pinzon-Ortiz M; Murakami M; Dobson JR; Quinn D; Wagner JP; Rong X; Shaw P; Dammassa E; Guan W; Dranoff G; Cao A; Fulton RB; Leonardo S; Fraser K; Kangas TO; Ottoson N; Bose N; Huhn RD; Graff J; Lowe J; Gorden K; Uhlik M; Vitale LA; O’Neill T; Widger J; Crocker A; He L-Z; Weidlick J; Sundarapandiyan K; Ramakrishna V; Storey J; Thomas LJ; Goldstein J; Marsh HC; Keler T; Grailer J; Gilden J; Stecha P; Garvin D; Hartnett J; Fan F; Cong M; Cheng Z-JJ; Hinner MJ; Aiba R-SB; Schlosser C; Jaquin T; Allersdorfer A; Berger S; Wiedenmann A; Matschiner G; Schüler J; Moebius U; Rothe C; Shane OA; Horton B; Spranger S; Gajewski TF; Moreira D; Adamus T; Zhao X; Swiderski P; Pal S; Kortylewski M; Kosmides A; Necochea K; Schneck J; Mahoney KM; Shukla SA; Patsoukis N; Chaudhri A; Pham H; Hua P; Bu X; Zhu B; Hacohen N; Wu CJ; Fritsch E; Boussiotis VA; Freeman GJ; Moran AE; Polesso F; Lukaesko L; Weinberg A; Rådestad E; Egevad L; Mattsson J; Sundberg B; Henningsohn L; Levitsky V; Uhlin M; Rafelson W; Reagan JL; Fast L; Sasikumar P; Sudarshan N; Ramachandra R; Gowda N; Samiulla D; Chandrasekhar T; Adurthi S; Mani J; Nair R; Dhudashia A; Gowda N; Ramachandra M; Sankin A; Gartrell B; Cumberbatch K; Huang H; Stern J; Schoenberg M; Zang X; Swanson R; Kornacker M; Evans L; Rickel E; Wolfson M; Valsesia-Wittmann S; Shekarian T; Simard F; Nailo R; Dutour A; Jallas A-C; Caux C; Marabelle A
Editorial comment: JOURNAL OF CLINICAL INVESTIGATION. 2016;126(2):480-482
TAP-ing into TIEPPs for cancer immunotherapy
Kiessling R
Conference publication: EUROPEAN JOURNAL OF IMMUNOLOGY. 2016;46:946-947
GMP-production of an allogenic DC-based cancer vaccine (INTUVAX) for treatment of patients with metastatic kidney-or primary liver cancer. Comparison of two production platforms for DC-generation
Adamson L; Andersson B; Kiessling R; Nasman-Glaser B; Karlsson-Parra A
Conference publication: JOURNAL OF TRANSLATIONAL MEDICINE. 2016;14
Ipilimumab treatment results in CD4 T cell activation that is concomitant with a reduction in Tregs and MDSCs
de Coana YP; Wolodarski M; Yoshimoto Y; Gentilcore G; Poschke I; Masucci GV; Hansson J; Kiessling R
Conference publication: CANCER IMMUNOLOGY RESEARCH. 2016;4(1):a071
Immune monitoring of ipilimumab treated patients reveals enhanced CD4+T cell activation correlated with diminished MDSCs
de Coana YP; Wolodarski M; Yoshimoto Y; Gentilcore G; Poschke I; Masucci GV; Hansson J; Kiessling R
Meeting abstract: CANCER IMMUNOLOGY RESEARCH. 2016;4(1):b071
Enhanced IL-12 production and T cell stimulation ability by dendritic cells matured in presence of GMP-grade Toll-like receptor ligands and IFN-γ
Adamson L; Sarhan D; Choudhary B; Mellef J; Nystrom M; Edback U; Vermeij R; Scurti G; Nishimura M; Lundqvist A; Kiessling R; Lovgren T
Conference publication: PEDIATRIC BLOOD AND CANCER. 2016;63:S28
Combination Therapy of Anti-PD-1 Antibody and CSF-1R Inhibitor Reverses Induction of Suppressive Myeloid Cells and Controls Spontaneous Neuroblastoma Progression
Eissler N; Mao Y; Brodin D; Reutersward P; Svahn HA; Johnsen JI; Kiessling R; Kogner P
Review: TRENDS IN MOLECULAR MEDICINE. 2015;21(8):482-491
Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system
de Coana YP; Choudhury A; Kiessling R
Book chapter: DEVELOPMENTS IN T CELL BASED CANCER IMMUNOTHERAPIES: CANCER DRUG DISCOVERY AND DEVELOPMENT. 2015;p. 211-229
T Cell Blockade Immunotherapy Against Cancer and Abscopal Effect in Combination Therapy
Masucci GV; De Petris L; Lundqvist A; Kiessling R; Lewensohn R
Conference publication: PEDIATRIC BLOOD AND CANCER. 2015;62:S149
NEUROBLASTOMA IMMUNOTHERAPY TARGETING CSF-1R REVERSES INDUCTION OF SUPPRESSIVE MYELOID CELLS AND CONTROLS AGGRESSIVE TUMOR PROGRESSION
Eissler N; Mao Y; Johnsen JI; Kiessling R; Kogner P
Review: ONCOTARGET. 2014;5(24):12472-12508
Classification of current anticancer immunotherapies
Galluzzi L; Vacchelli E; Bravo-San Pedro J-M; Buque A; Senovilla L; Baracco EE; Bloy N; Castoldi F; Abastado J-P; Agostinis P; Apte RN; Aranda F; Ayyoub M; Beckhove P; Blay J-Y; Bracci L; Caignard A; Castelli C; Cavallo F; Celis E; Cerundolo V; Clayton A; Colombo MP; Coussens L; Dhodapkar MV; Eggermont AM; Fearon DT; Fridman WH; Fucikova J; Gabrilovich DI; Galon J; Garg A; Ghiringhelli F; Giaccone G; Gilboa E; Gnjatic S; Hoos A; Hosmalin A; Jaeger D; Kalinski P; Kaerre K; Kepp O; Kiessling R; Kirkwood JM; Klein E; Knuth A; Lewis CE; Liblau R; Lotze MT; Lugli E; Mach J-P; Mattei F; Mavilio D; Melero I; Melief CJ; Mittendorf EA; Moretta L; Odunsi A; Okada H; Palucka AK; Peter ME; Pienta KJ; Porgador A; Prendergast GC; Rabinovich GA; Restifo NP; Rizvi N; Sautes-Fridman C; Schreiber H; Seliger B; Shiku H; Silva-Santos B; Smyth MJ; Speiser DE; Spisek R; Srivastava PK; Talmadge JE; Tartour E; Van der Burg SH; Van den Eynde BJ; Vile R; Wagner H; Weber JS; Whiteside TL; Wolchok JD; Zitvogel L; Zou W; Kroemer G
Conference publication: BLOOD. 2014;124(21):4140
Regulation of Natural Killer Cell Responses By Dendritic Cells Via Lymphotoxin-Alpha, Interleukin-12, and Tumor Growth Factor-Beta
Sarhan D; Palma M; Mao Y; Adamson L; Kiessling R; Mellstedt H; Osterborg A; Lundqvist A
Review: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2014;63(9):977-983
Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy
de Coana YP; Masucci G; Hansson J; Kiessling R
Review: JOURNAL OF INTERNAL MEDICINE. 2014;276(2):154-170
Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells
Mao Y; Poschke I; Kiessling R
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(15):3085
Intratumoral vaccination with activated allogeneic dendritic cell in patients with newly diganosed metastatic renal cell carcinoma (mRCC)
Magnusson A; Laurell A; Lonnemark M; Brekkan E; Adamson L; Tolf A; Andersson B; Wallgren A; Kiessling R; Karlsson-Parra A
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(15):tps3118
A phase I study of adoptive T-cell therapy with or without dendritic cell vaccination in patients with metastatic melanoma.
Tell R; Mattson J; Adamson L; Poschke I; Engstrom M; Lovpren T; Hansson J; Masuccl GV; Lundqvist A; Kiessling R
Editorial comment: CLINICAL CANCER RESEARCH. 2014;20(6):1401-1403
Myeloid Suppressors Decrease Melanoma Survival by Abating Tumor-Fighting T Cells
Kiessling R; Mao Y; de Coana YP
Conference publication: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2014;2(Suppl 3):p224
Inhibiton of tumor-derived prostaglandin-e2 prevents the induction of human myeloid-derived suppressor cells (MDSCs) and rescues anti-tumor immunity
Mao Y; Sarhan D; Poschke I; Lundqvist A; Kiessling R
Corrigendum: CANCER IMMUNOLOGY RESEARCH. 2013;1(6):438
Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid Derived Suppressor Cells as well as Their Arginase1 Production (vol 1, pg 158, 2013)
de Coana YP; Poschke I; Gentilcore G; Mao Y; Nystrom M; Hansson J; Masucci GV; Kiessling R
Review: TRENDS IN MOLECULAR MEDICINE. 2013;19(11):677-684
The two sides of HER2/neu: immune escape versus surveillance
Seliger B; Kiessling R
Review: JOURNAL OF TRANSLATIONAL MEDICINE. 2013;11:247
HLA-dependent tumour development: a role for tumour associate macrophages?
Marchesi M; Andersson E; Villabona L; Seliger B; Lundqvist A; Kiessling R; Masucci GV
Editorial comment: ONCOIMMUNOLOGY. 2013;2(8):e25157
Cyclooxygenase-2 Steering force of myeloid-derived suppressor cells in cancer?
Mao Y; Poschke I; Kiessling R
Review: CELL DEATH AND DISEASE. 2013;4(6):e688
Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation
Kono K; Mimura K; Kiessling R
Meeting abstract: CANCER RESEARCH. 2013;73:b70
Generation of MAGE-A4 230-239 peptide-specific cytotoxic T lymphocytes using an alloreactive approach.
Lovgren T; Mao Y; Boschen M-L; Allerbring EB; Achour A; Poschke I; Kiessling R
Meeting abstract: CANCER RESEARCH. 2013;73:b41
Analysis of immune responses and tumor protection in C57/Bl6 mice immunized with altered CD8 survivin peptide ligands.
de Coana YP; Duru AD; Lladser A; Achour A; Kiessling R
Meeting abstract: CANCER RESEARCH. 2013;73:a63
Melanoma-educated CD14+monocytes become myeloid-derived suppressor cell-like and are potent inhibitors of autologous T cells through Cox-2 production and STAT-3 signaling.
Mao Y; Poschke I; de Coana YP; Wennerberg E; Lundqvist A; Kiessling R
Conference publication: BONE MARROW TRANSPLANTATION. 2013;48:S73
Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic haematopoietic stem cell transplantation
Jitschin R; Mougiakakos D; Linder S; von Bahr L; Moll G; Voelkl S; Kiessling R; Ringden O; Le Blanc K
Editorial comment: ONCOIMMUNOLOGY. 2012;1(7):1200-1201
Opposing consequences of signaling through EGF family members Escape from CTLs could be a bait for NK cells
Kiessling R; Okita R; Mougiakakos D; Mao Y; Sarhan D; Wennerberg E; Seliger B; Lundqvist A; Mimura K; Kono K
Review: CLINICAL IMMUNOLOGY. 2012;144(3):250-268
On the armament and appearances of human myeloid-derived suppressor cells
Poschke I; Kiessling R
Editorial comment: JOURNAL OF TRANSLATIONAL MEDICINE. 2012;10:104
Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours
Masucci GV; Wersall P; Kiessling R; Lundqvist A; Lewensohn R
Other: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2012;61(4):587-591
First International Meeting of the Thematic Centre for Immune Modulatory Therapies for Autoimmunity and Cancer (IMTAC) 13-14 June 2011, Ljusterö, Sweden.
Choudhury A; Höglund P; Kiessling R; Kärre K; Lundqvist A; Malmberg K; Mellstedt H; Scheynius A; Winqvist O; Osterborg A
Conference publication: ANNALS OF ONCOLOGY. 2012;23:541
HER SIGNALING EFFECTS ON THE NK CELL-MEDIATED CYTOTOXICITY VIA REGULATION OF MHC CLASS I-RELATED CHAIN A/ B IN CANCER CELLS
Okita R; Mougiakakos D; Yasuda K; Maeda A; Yukawa T; Saisho S; Hirami Y; Shimizu K; Nakata M; Kiessling R
Conference publication: IMMUNOLOGY. 2012;137:715-716
Low affinity HLA-A2 restricted melanocortin 1 receptor-derived peptides are recognized by melanoma-specific CTLs and TILs from melanoma patients
Gonzalez FE; Ramirez M; Allerbring EB; Duru AD; Poschke I; Kiessling R; Achour A; Salazar-Onfray F
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 2011;47:S331
HER2-HER3 Signaling Pathway Regulates NK Cell-mediated Cytotoxicity via MHC Class I-related Chain A/ B in Human Breast Cancer Cells
Okita R; Ando T; Mougiakakos D; Mao Y; Lundqvist A; Kiessling R
Review: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2011;60(8):1161-1171
Camouflage and sabotage: tumor escape from the immune system
Poschke I; Mougiakakos D; Kiessling R
Review: ADVANCES IN CANCER RESEARCH. 2011;111:1-37
Is Survivin the Potential Achilles' Heel of Cancer?
Lladser A; Sanhueza C; Kiessling R; Quest AFG
Editorial comment: JOURNAL OF MOLECULAR MEDICINE. 2010;88(11):1081-1084
Designer lymphocytes to fight cancer: a helping hand from modern molecular biology
Kiessling R
Review: ADVANCES IN CANCER RESEARCH. 2010;107:57-117
Regulatory T Cells in Cancer
Mougiakakos D; Choudhury A; Lladser A; Kiessling R; Johansson CC
Letter: BLOOD. 2009;114(2):488-489
Resistance of naturally occurring regulatory T cells toward oxidative stress: possible link with intracellular catecholamine content and implications for cancer therapy Response
Mougiakakos D; Johansson CC; Kiessling R
Conference publication: JOURNAL OF IMMUNOTHERAPY. 2009;32(9):977
Ad-E2A Preventive and Therapeutic Immunizations Confer Tumor Protection or Delay Tumor Growth in Transplantable HER-2+Mouse Tumor Models
Triulzi C; Veituani S; Cuicio C; Seibt J; Cavallo F; Wei W-Z; Kiessling R
Review: ADVANCES IN CANCER RESEARCH. 2009;102:197-227
Oxidative Stress and Lymphocyte Persistence: Implications in Immunotherapy
Mehrotra S; Mougiakakos D; Johansson CC; Voelkel-Johnson C; Kiessling R
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2008;26(15):9050
Ancestral HLA haplotypes 62.1 and 8.1 as negative prognostic factors in patients with metastatic malignant melanoma
Helgadottir H; Andersson E; Hansson J; Kiessling R; Masucci GV
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2008;26(15):16544
Survival rates in HLA-A2 positive patients, with stage III-IV serous adenocarcinomas of the ovary, correlates with increased expression of COX-2 and iNOS, loss of MHC Class I and II and defects of the antigen processing mechanisms at the tumour level
Andersson E; Johansson CC; Villabona L; Kanter L; Helgadottir H; Dalianis T; Bergfeldt K; Seliger B; Ferrone S; Kiessling R; Masucci GV
Editorial comment: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2008;57(4):593-599
Progress in vaccination against cancer-7: report of the meeting in Stockholm, September 10-11, 2007
Kiessling R; De Geer A; Johansson C; Poschke I; Triulzi C; Vertuani S
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2008;68(2):185
Altered receptor repertoire and impaired function of tumor associated natural killer cells in ovarian carcinoma
Carlsten M; Norell H; Bryceson Y; Schedvins K; Ljunggren H-G; Kiessling R; Malmberg K-J
Editorial comment: BRITISH JOURNAL OF SURGERY. 2007;94(12):1449-1450
Cancer vaccines.
Kiessling R; Choudhury A
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2007;25(18)
Lack of p21/Waf-1 expression and lymphocyte infiltration in primary ovarian cancer correlate with the somatic HLA-A2 expression
Andersson E; Villabona L; Kanter L; Gamzatova Z; Kiessling R; Dalianis T; Bergfeldt K; Masucci GV
Other: JOURNAL OF IMMUNOLOGY. 2005;174(11):6566-6569
Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy (Reprinted from Nature 319: 675-678 (1986))
Kärre K; Ljunggren HG; Piontek G; Kiessling R
Review: BREAST DISEASE. 2004;20:25-31
Her-2/neu as a paradigm of a tumor-specific target for therapy.
Choudhury A; Kiessling R
Editorial comment: GENE THERAPY. 2004;11(21):1549-1550
HER-2/neu immunotherapies - Take two - get more: optimization strategies for HER-2/neu-based immunotherapies inhibiting carcinogenesis
Seliger B; Kiessling R
Editorial comment: TRENDS IN IMMUNOLOGY. 2002;23(3):130-135
Heat-shock proteins as activators of the innate immune system
Wallin RPA; Lundqvist A; Moré SH; von Bonin A; Kiessling R; Ljunggren HG
Review: ADVANCES IN CANCER RESEARCH. 2002;85:101-144
Cellular immunity to the Her-2/neu protooncogene
Kiessling R; Wei WZ; Herrmann F; Lindencrona JA; Choudhury A; Kono K; Seliger B
Other: TRENDS IN MOLECULAR MEDICINE. 2000;6(9):344-346
Have tumor cells learnt from microorganisms how to fool the immune system? Escape from immune surveillance of tumors and microorganisms: emerging mechanisms and shared strategies.
Kiessling R; Pawelec G; Welsh RM; Barry JD; Ferrone S
Review: CRITICAL REVIEWS IN ONCOGENESIS. 2000;11(2):97-133
Escape mechanisms in tumor immunity:: A year 2000 update
Pawelec G; Heinzel S; Kiessling R; Müller L; Ouyang Q; Zeuthen J
Conference publication: CELL STRESS AND CHAPERONES. 2000;5(4):374
Human HSP70 efficiently load monocytes with antigenic peptides and allow specific recognition by anti-tumor T cells.
Castelli C; Dalerba P; Ciupitu AT; Rini F; Rivoltini L; Mazzocchi A; Kiessling R; Parmiani G
Review: CRITICAL REVIEWS IN ONCOGENESIS. 1999;10(1-2):83-127
Cells and cytokines in immunotherapy and gene therapy of cancer
Pawelec G; Rees RC; Kiessling R; Madrigal A; Dodi A; Baxevanis C; Gambacorti-Passerini C; Masucci G; Zeuthen J
Published conference paper: RESEARCH IN IMMUNOLOGY. 1998;149(9):877-879
Protective T-cell responses against tumours
Melief C; Annels N; Dunbar R; Forni G; Kiessling R; Ricciardi-Castagnoli P; Rickinson A; van den Eynde B
Review: LAKARTIDNINGEN. 1997;94(17):1595-1600
[A scientist's day-dream or future reality? Specific immunotherapy against cancer].
Kiessling R; Kärre K
Editorial comment: GUT. 1997;40(1):153-154
Signals from lymphocytes in colon cancer
Kiessling R
Review: CRITICAL REVIEWS IN ONCOGENESIS. 1997;8(2-3):111-142
Escape from host-antitumor immunity
Pawelec G; Zeuthen J; Kiessling R
Conference publication: HUMAN IMMUNOLOGY. 1996;47(1-2):O804
IL-10 suppress TAP function and make cells NK sensitive
Charo J; Petersson M; Salazar F; Qin ZH; Blankenstein T; Kiessling R
Published conference paper: ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. 1995;756:406-409
HUMAN GAMMA-DELTA T-CELLS IN THE EPITHELIUM OF THE GUT AND IN THE INFLAMED SYNOVIAL TISSUE PREFERENTIALLY EXPRESS THE V-GAMMA-8 T-CELL RECEPTOR CHAIN
SODERSTROM K; BUCHT A; HALAPI E; LUNDQVIST C; GRONBERG A; NILSSON E; ORSINI DLM; VANDEWAL Y; KONING F; HAMMARSTROM ML; KIESSLING R
Published conference paper: ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. 1995;756:395-399
PHENOTYPE AND CYTOKINE PROFILE OF INTRAEPITHELIAL LYMPHOCYTES IN HUMAN SMALL AND LARGE-INTESTINE
LUNDQVIST C; BARANOV V; SODERSTROM K; ATHLIN L; KIESSLING R; HAMMARSTROM S; HAMMARSTROM ML
Conference publication: JOURNAL OF CELLULAR BIOCHEMISTRY. 1995;:106
CONVERSION OF A MOUSE LYMPHOMA TO A CTL RESISTANT, NK SENSITIVE PHENOTYPE WITH LOW MHC-1 EXPRESSION AS A RESULT OF IL-10 TREATMENT OR TRANSFECTION
SALAZAR F; FRANKSSON L; MATSUDA M; KARRE K; KIESSLING R
Conference publication: JOURNAL OF CELLULAR BIOCHEMISTRY. 1994;:233
EPSTEIN-BARR-VIRUS ENCODED MEMBRANE-PROTEIN LMP1 INDUCES INTERLEUKIN-10 PRODUCTION IN BURKITTS-LYMPHOMA LINES
SJOBERG J; NAKAGOMI H; DOLCETTI R; BEJARANO MT; PISA P; KIESSLING R; MASUCCI MG
Conference publication: JOURNAL OF CELLULAR BIOCHEMISTRY. 1993;:115
CYTOKINE EXPRESSION IN HUMAN RENAL-CELL CARCINOMAS - LACK OF IL-2 EXPRESSION AND SELECTIVE EXPRESSION OF IL-10 MESSENGER-RNA IN TUMOR-TISSUE
KIESSLING R; NAKAGOMI H; PISA P; PISA EK; YAMAMOTO Y; HALAPI E; BACKLIN K; JUHLIN C
Conference publication: JOURNAL OF CELLULAR BIOCHEMISTRY. 1993;:144
ANALYSIS OF CYTOKINE GENE-EXPRESSION IN RHEUMATOID-ARTHRITIS USING QUANTITATIVE POLYMERASE CHAIN-REACTION
BUCHT A; SODERSTROM K; PISA P; KIESSLING R; GRONBERG A
Conference publication: JOURNAL OF CELLULAR BIOCHEMISTRY. 1993;:104
IMMUNIZATION AGAINST TUMOR AND MINOR HISTOCOMPATIBILITY ANTIGENS BY NATURALLY PROCESSED PEPTIDES
FRANKSSON L; PETERSSON M; KIESSLING R; KARRE K
Conference publication: ARTHRITIS & RHEUMATOLOGY. 1992;35(9):S145
THE V-DELTA-2 AND V-DELTA-2 T-CELL RECEPTOR REPERTOIRES IN SYNOVIAL-FLUID AND PERIPHERAL-BLOOD OF A PATIENT WITH JUVENILE RHEUMATOID-ARTHRITIS
SODERSTROM K; BUCHT A; HULTMAN T; UHLEN M; NILSSON E; GRONBERG A; KIESSLING R
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1992;36(4):627
IMMUNIZATION AGAINST TUMOR AND MINOR HISTOCOMPATIBILITY ANTIGENS BY NATURALLY PROCESSED PEPTIDES
FRANKSSON L; PETERSSON M; KIESSLING R; KARRE K
Book chapter: T LYMPHOCYTES: NATO SCIENCE SERIES A:. 1992;p. 235-240
Oligoclonal T Cells Expressing the TCR V-ß 6 Gene Product Following IL-2 Culture of Ovarian Carcinoma Derived Lymphocytes
Halapi E; Jeddi-Tehrani M; Grunewald J; Andersson R; Hising C; Masucci G; Mellstedt H; Kiessling R
Book chapter: T LYMPHOCYTES: NATO SCIENCE SERIES A:. 1992;p. 241-246
Comparisons of the V-Delta-1 Expressing T-Cells in Synovial Fluid and Peripheral Blood of Patients with Chronic Arthritis
Söderström K; Bucht A; Hultman T; Uhlén M; Nilsson E; Grönberg A; Jindal S; Kiessling R
Conference publication: THE FASEB JOURNAL. 1992;6(4):A1151
SELECTIVE EXPRESSION OF IL-10, IFN-GAMMA AND GM-CSF IN OVARIAN-CANCER BIOPSIES
PISA EK; PISA P; HALAPI E; GERDIN E; HISING C; BUCHT A; GERDIN B; KIESSLING R
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1990;32(4):408
INCREASED SUSCEPTIBILITY OF IFN-GAMMA TREATED NEUROBLASTOMA-CELLS TO LYSIS BY LYMPHOKINE ACTIVATED KILLER-CELLS - POSSIBLE PARTICIPATION OF ICAM-1 INDUCTION ON TARGET-CELLS
NAGANUMA H; KIESSLING R; PATARROYO M; HANSSON M; HANDGRETINGER R; GRONBERG A
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1990;32(4):408
TUMOR SPECIFIC T-CELL CLONES DERIVED FROM THE ASCITES-FLUID OF A PATIENT WITH OVARIAL CELL-CARCINOMA
NAGANUMA H; HALAPI E; MASSUCCI G; HANSSON M; WERSALL P; HISING C; MELLSTEDT H; KIESSLING R
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1990;32(4):394
MONOCLONAL-ANTIBODIES AGAINST MYCOBACTERIAL HSP65 CROSS-REACTIVE WITH INTRACELLULAR ANTIGENS IN HUMAN TUMOR-CELLS
GRONBERG A; BUCHT A; ARVIDSSON B; LINDEN AM; SMEDEGARD G; KIESSLING R
Book chapter: THE BIOLOGY OF THE INTERFERON SYSTEM 1986. 1987;p. 257-263
Phenotype of γ-Interferon Producing Leukocytes
Andersson U; Laskay T; Andersson J; Kiessling R; DeLey M
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1987;26(3):312
PARTIAL CHARACTERIZATION OF A CELL-SURFACE ANTIGEN INDUCIBLE BY INTERFERON-GAMMA
GRONBERG A; HALAPI E; PETERSSON M; PATARROYO M; KIESSLING R
Conference publication: IMMUNOBIOLOGY. 1987;175(1-2):111
PARTIAL CHARACTERIZATION OF A CELL-SURFACE ANTIGEN INDUCIBLE BY INTERFERON-GAMMA
GRONBERG A; HALAPI E; PETERSSON MGE; PATARROYO M; KIESSLING R
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1987;26(3):312
NATURAL-KILLER-CELLS AS REGULATORS OF HEMATOPOIESIS
HANSSON M; PETERSSON M; KOO GC; WIGZELL H; KIESSLING R
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1987;26(3):325
AN ACTIVE T-CELL INDEPENDENT MECHANISM ENHANCES MHC CLASS-I TRANSCRIPTION AND EXPRESSION ON A MOUSE T-CELL LYMPHOMA INVIVO
PETERSSON MGE; KARRE K; COCHET M; KOURILSKY P; KIESSLING R
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1987;26(3):325
EFFECT OF TUMOR-NECROSIS-FACTOR AND INTERFERON-GAMMA ON NK SUSCEPTIBILITY AND HLA EXPRESSION ON HUMAN-LEUKEMIA CELLS
PETERSSON M; FERM M; KIESSLING R; GRONBERG A
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1987;26(3):310
EFFECT OF INTERFERON TREATMENT ON TUMOR-CELL SUSCEPTIBILITY TO LYMPHOKINE ACTIVATED KILLER (LAK) CELLS
FERM M; TSAI L; KIESSLING R; GRONBERG A
Conference publication: JOURNAL OF CELLULAR BIOCHEMISTRY. 1986;:101
EVIDENCE FOR INCREASED PRODUCTION OF IFN-GAMMA AND OTHER FACTORS SUPPRESSING HEMATOPOIESIS IN APLASTIC-ANEMIA PATIENTS
KIESSLING R; LASKAY T; HANSSON M; PORWIT A; BJORKHOLM M
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1986;24(4):468
INTERFERON AND BUTYRATE TREATMENT LEADS TO A DECREASED SENSITIVITY OF NK TARGET-CELLS TO LYSIS BY HOMOLOGOUS BUT NOT BY HETEROLOGOUS EFFECTOR-CELLS
LASKAY T; KIESSLING R
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1986;24(4):466
MOLECULAR AND IMMUNOLOGICAL ANALYSIS OF MHC CLASS-I VARIANT TUMOR LINES
KARRE K; LJUNGGREN HG; COCHET M; KOURILSKY P; KIESSLING R; PAABO S; PIONTEK G; KLING G
Conference publication: TUMOUR BIOLOGY. 1986;7(4):294
MONONUCLEAR-CELLS PRODUCE GROWTH-INHIBITORS OF HEMATOPOIESIS
HANSSON M; LASKAY T; KIESSLING R
Book chapter: IMMUNE REGULATION: EXPERIMENTAL BIOLOGY AND MEDICINE. 1985;p. 75-78
Human Natural Killer Cells
Kiessling R; Pross H
Conference publication: IMMUNOBIOLOGY. 1984;167(1-3):32
NATURAL-KILLER (NK) CELLS CAN INHIBIT THE OUTGROWTH OF NORMAL BONE-MARROW PROGENITOR CELLS IN MAN AND MOUSE
PISA P; DAHL C; HANSSON M; KIESSLING R
Conference publication: IMMUNOBIOLOGY. 1984;167(1-3):43-44
ACTIVATION OF CELL-MEDIATED-IMMUNITY BY ABSENCE OR DELETED EXPRESSION OF NORMAL CELLULAR GENE-PRODUCTS, IE BY NO SELF RATHER THAN NON SELF
KARRE K; LJUNGGREN HG; PIONTEK G; KIESSLING R; KLEIN G; TANIGUCHI K; GRONBERG A
Conference publication: IMMUNOBIOLOGY. 1984;167(1-3):191-192
NATURAL CELL-MEDIATED-IMMUNITY AGAINST MHC CLASS-I VARIANTS OF THE NK-SENSITIVE YAC-1 T-LYMPHOMA
PIONTEK GE; TANIGUCHI K; LJUNGGREN HG; GRONBERG A; KIESSLING R; KARRE K
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1983;18(1):72
INTERFERON MEDIATED MODULATION OF NK SENSITIVITY IN A HUMAN HYBRID CELL-LINE DURING SELECTION WITH NK-CELLS
GRONBERG A; KIESSLING R; MASUCCI G; KLEIN G
Conference publication: THE FASEB JOURNAL. 1983;42(5):1339
NK-ACTIVITY AGAINST NORMAL HUMAN BONE-MARROW
HANSSON M; BERAN M; KIESSLING R
Book chapter: NK CELLS AND OTHER NATURAL EFFECTOR CELLS. 1982;p. 705-711
NON-NK LEUKOCYTES DEMONSTRATE NK-PATTERNED BINDING
Piontek GE; Kiessling R; Grönberg A; Ährlund-Richter L
Book chapter: NK CELLS AND OTHER NATURAL EFFECTOR CELLS. 1982;p. 1077-1084
NATURAL KILLING OF HEMATOPOIETIC CELLS11Supported by National Cancer Institute, DHEW CA 26782 and the Swedish Cancer Society.
Hansson M; Kiessling R; Beran M
Book chapter: NK CELLS AND OTHER NATURAL EFFECTOR CELLS. 1982;p. 1369-1378
THE BEIGE MODEL IN STUDIES OF NATURAL RESISTANCE TO SYNGENEIC, SEMISYNGENEIC, AND PRIMARY TUMORS11Supported by NIH grants CA 14054–06 and CA 26782–02, and by grants from the Swedish Cancer Society.
Kärre K; Gunnar OK; Rolf K; Shmuel A; George K
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1982;16(5):447
EXPRESSION OF NK-PATTERNED BINDING BY VARIOUS MOUSE LEUKOCYTE POPULATIONS
PIONTEK G; KIESSLING R; AHRLUND-RICHTER L; GRONBERG A
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1982;15(1):133
INTERFERON AS A MODULATOR OF THE MOUSE NK SYSTEM - ACTIVATION OF EFFECTOR-CELLS BUT PROTECTION OF TARGET-CELLS
KIESSLING R; WELSH R; YOGEESWARAN G
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1982;15(1):133
VARIANTS FROM A MOUSE LYMPHOMA SELECTED FOR DECREASED SENSITIVITY TO NATURAL-KILLER CELL-LYSIS
ERIKSSON E; GRONBERG A; KIESSLING R; HANSSON M
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1982;15(1):131
NK SURVEILLANCE OF PRIMITIVE NORMAL-CELLS IN THE THYMUS AND BONE-MARROW
HANSSON M; KIESSLING R
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1982;15(1):131
MOUSE NATURAL ANTIBODIES AND NATURAL-KILLER (NK) CELLS SHOW SIMILAR SPECIFICITY AGAINST INVIVO GROWN LYMPHOMA SUBLINES
GRONBERG A; KIESSLING R; ERIKSSON E; KLEIN GO
Book chapter: NK CELLS AND OTHER NATURAL EFFECTOR CELLS. 1982;p. 765-770
SURFACE SIALIC ACID OF TUMOR CELLS INVERSELY CORRELATES WITH SUSCEPTIBILITY TO NATURAL KILLER CELL MEDIATED LYSIS11Supported by NIH grants CA19312, AI12438, CA26782, CA-26752, and a grant from Swedish Cancer Society.
Yogeeswaran G; Raymond MW; Gronberg A; Kiessling R; Patarroyo M; George K; Gidlund M; Wigzell H; Nilsson K
Book chapter: DIFFERENTIATED LYMPHOCYTE FUNCTIONS: CHEMICAL IMMUNOLOGY AND ALLERGY. 1981;p. 113-140
Natural Killer Cells (Part 3 of 4)
Roder JC; Karre K; Kiessling R
Book chapter: DIFFERENTIATED LYMPHOCYTE FUNCTIONS: CHEMICAL IMMUNOLOGY AND ALLERGY. 1981;p. 91-112
Natural Killer Cells (Part 2 of 4)
Roder JC; Karre K; Kiessling R
Book chapter: DIFFERENTIATED LYMPHOCYTE FUNCTIONS: CHEMICAL IMMUNOLOGY AND ALLERGY. 1981;p. 66-90
Natural Killer Cells (Part 1 of 4)
Roder JC; Karre K; Kiessling R
Book chapter: CHEMICAL IMMUNOLOGY AND ALLERGY. 1981;p. 66-159
Natural killer cells.
Roder JC; Karre K; Kiessling R
Book chapter: DIFFERENTIATED LYMPHOCYTE FUNCTIONS: CHEMICAL IMMUNOLOGY AND ALLERGY. 1981;p. 141-159
Natural Killer Cells (Part 4 of 4)
Roder JC; Karre K; Kiessling R
Book chapter: CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY. 1981;p. 107-123
Surveillance of primitive cells by natural killer cells.
Kiessling R; Wigzell H
Book chapter: GENETIC CONTROL OF NATURAL RESISTANCE TO INFECTION AND MALIGNANCY. 1980;p. 389-404
GENETIC CONTROL OF IN VITRO NK REACTIVITY AND ITS RELATIONSHIP TO IN VIVO TUMOR RESISTANCE
Kiessling R; Karre K; Klein G
Book chapter: NATURAL CELL-MEDIATED IMMUNITY AGAINST TUMORS. 1980;p. 855-872
INTERACTION BETWEEN NK CELLS AND NORMAL TISSUE: DEFINITION OF A NK-SENSITIVE THYMOCYTE POPULATION
Hansson M; Kiessling R; Welsh R
Book chapter: NATURAL CELL-MEDIATED IMMUNITY AGAINST TUMORS. 1980;p. 671-685
ACTIVATED NATURAL KILLER CELLS INDUCED DURING THE LYMPHOCYTIC CHORIOMENINGITIS VIRUS INFECTION IN MICE
Welsh RM; Kiessling RW
Book chapter: NATURAL CELL-MEDIATED IMMUNITY AGAINST TUMORS. 1980;p. 963-972
MODIFICATION OF TARGET SUSCEPTIBILITY TO ACTIVATED MOUSE NK CELLS BY INTERFERON AND VIRUS INFECTIONS
Welsh RM; Kiessling RW
Book chapter: GENETIC CONTROL OF NATURAL RESISTANCE TO INFECTION AND MALIGNANCY. 1980;p. 467-475
HYBRID RESISTANCE TO PARENTAL TUMORS: INFLUENCE OF HOST AND TUMOR GENOTYPE AND TUMOR DERIVATION
Klein GO; Klein G; Kiessling R
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1979;10(4):367-368
NATURAL NK-CELL TARGETS IN THE MOUSE THYMUS
HANSSON M; KARRE K; KIESSLING R; RODER J; ANDERSSON B; HAYRY P
Book chapter: ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. 1979;p. 745-750
A model of target cell recognition and lysis by natural killer cells.
Roder JC; Kiessling R
Book chapter: CONTEMP TOP IMMUNOBIOL. 1978;p. 171-201
Natural killer cells in the mouse: an alternative immune surveillance mechanism?
Kiessling R; Haller O
Conference publication: ZEITSCHRIFT FUR IMMUNITATSFORSCHUNG-IMMUNOBIOLOGY. 1978;154(4):356
TARGET-EFFECTOR CELL-INTERACTION IN MOUSE NATURAL KILLER CELL SYSTEM
RODER JC; KIESSLING R
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1977;6(6-7):705
DONOR GENOTYPE DEPENDENCE OF ADOPTIVELY TRANSFERRED NATURAL KILLER-CELL ACTIVITY
HALLER O; ORN A; ANDERSSON B; KIESSLING R; WIGZELL H
Book chapter: THE ROLE OF PRODUCTS OF THE HISTOCOMPATIBILITY GENE COMPLEX IN IMMUNE RESPONSES. 1976;p. xi-xiv
Participants
Amos DB; Armerding D; Bach FH; Benacerraf B; Bechtol K; Cunningham BA; Dausset J; Dorf ME; Dupont B; Gasser DL; Gershon R; Green I; Grey H; Hämmerling G; Hood L; Janicki BW; Kapp J; Katz DH; Kiessling R; Klein G; Klein J; Kunkel HG; Lieberman R; Maurer PH; McDevitt HO; Meo T; Miller JFAP; Möller E; Mozes E; Munro AJ; Nathenson SG; Nossal GJV; Paul WE; Pierce CW; Rajewsky K; Rosenthal A; Sachs DH; Sela M; Shearer GM; Shevach EM; Shreffler DC; Simonsen M; Stimpfling JH; Strominger JL; Tada T; Taussig M; Uhr JW; Unanue ER; von Boehmer H; van Rood JJ; Vitetta E; Wigzell H; Wilson DB; Yunis EJ; Zinkernagel RM
Book chapter: THE ROLE OF PRODUCTS OF THE HISTOCOMPATIBILITY GENE COMPLEX IN IMMUNE RESPONSES. 1976;p. 77-85
NATURAL KILLER CELLS IN THE MOUSE
KIESSLING R
Show more

Employments

Professor, Senior, Department of Oncology-Pathology, Karolinska Institutet, 2025-2025
Professor, Department of Oncology-Pathology, Karolinska Institutet, 2020-2024

Degrees and Education

Docent, Karolinska Institutet, 1978

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI